-
CANCER TREAT REV 2024 10.1016/j.ctrv.2024.102807
Central nervous system metastases in advanced non-small cell lung cancer: A review of the therapeutic landscape
Weller, M; Remon, J; Rieken, S; Vollmuth, P; Ahn, MJ; Minniti, G; Le Rhun, E; Westphal, M; Brastianos, PK; Soo, RA; Kirkpatrick, JP; Goldberg, SB; Öhrling, K; Hegi-Johnson, F; Hendriks, LEL
View PubMed
-
J THORAC ONCOL 2024 10.1016/j.jtho.2024.06.010
Neoadjuvant and Adjuvant Treatments for Early Stage Resectable NSCLC: Consensus Recommendations From the International Association for the Study of Lung Cancer
Spicer, JD; Cascone, T; Wynes, MW; Ahn, MJ; Dacic, S; Felip, E; Forde, PM; Higgins, KA; Kris, MG; Mitsudomi, T; Provencio, M; Senan, S; Solomon, BJ; Tsao, MS; Tsuboi, M; Wakelee, HA; Wu, YL; Chih-Hsin, J; Zhou, CC; Harpole, DH; Kelly, KL
View PubMed
-
BMC MED 2024 10.1186/s12916-024-03620-8
Updated overall survival and ctDNA analysis in patients with EGFR T790M-positive advanced non-small cell lung cancer treated with lazertinib in the phase 1/2 LASER201 study
Han, JY; Ahn, MJ; Lee, KH; Lee, YG; Kim, DW; Min, YJ; Kim, SW; Cho, EK; Kim, JH; Lee, GW; Lee, SS; Lee, NM; Jang, HW; Han, H; Park, H; Lee, J; Cho, BC
View PubMed
-
CANCER IMMUNOL IMMUN 2024 10.1007/s00262-024-03852-w
Biomarker role of thyroid irAE and PD-L1 positivity in predicting PD-1 blockade efficacy in patients with non-small cell lung cancer
Kim, HI; Kim, WG; Kim, M; Ko, NG; Jin, M; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Choi, YL; Jeon, MJ; Kim, TY; Kim, WB; Kim, SW; Lee, DH; Jang, SJ; Kim, SW; Chung, JH; Kim, TH; Lee, SH
View PubMed
-
ESMO OPEN 2024 10.1016/j.esmoop.2024.103668
A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification fi cation (KCSG AL19-17)
Kang, EJ; Yang, Y; Lee, S; Kim, YJ; Lim, SM; Ahn, MJ; Choi, YJ; Lee, Y; Kim, TM; Kim, I; Ahn, HK; Jeung, HC; Lee, SI; Oh, SY; Bae, WK; Ryu, H; Park, KH; Lee, KH
View PubMed
-
GENET EPIDEMIOL 2024 10.1002/gepi.22586
Predicting Lung Cancer in Korean Never-Smokers With Polygenic Risk Scores
Kim, J; Park, YS; Kim, JH; Hong, YC; Kim, YC; Oh, IJ; Jee, SH; Ahn, MJ; Kim, JW; Yim, JJ; Won, S
View PubMed
-
J CLIN ONCOL 2024 10.1200/JCO.24.00708
Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer (BLOSSOM)
Park, S; Baldry, R; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Kim, YJ; Lee, Y; Kim, DW; Kim, SW; Lee, KH; Lee, WJ; Choi, JW; Chong, K; Lee, JI; Gwon, SH; Son, NH; Ahn, MJ
View PubMed
-
FUTURE ONCOL 2024 10.1080/14796694.2024.2343272
The KEYVIBE program: vibostolimab and pembrolizumab for the treatment of advanced malignancies
Shapira-Frommer, R; Niu, JX; Perets, R; Peters, S; Shouse, G; Lugowska, I; Garassino, MC; Sands, J; Keenan, T; Zhao, B; Healy, J; Ahn, MJ
View PubMed
-
LANCET REG HEALTH-W 2024 10.1016/j.lanwpc.2024.101090
Drug development and evidence for lung cancer targeted therapy in Eastern Asia
Liu, SYM; Jin, ZY; Deng, JY; Zhong, SM; Ahn, MJ; Horinouchi, H; Li, YQ; Wu, YL
View PubMed
-
CANCERS 2024 10.3390/cancers16142525
18F-Fluorodeoxyglucose Positron Emission Tomography-Based Risk Score Model for Prediction of Five-Year Survival Outcome after Curative Resection of Non-Small-Cell Lung Cancer
Lim, CH; Um, SW; Kim, HK; Choi, YS; Pyo, HR; Ahn, MJ; Choi, JY
View PubMed
-
NEW ENGL J MED 2024 10.1056/NEJMoa2402614
Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC
Lu, S; Kato, T; Dong, XR; Ahn, MJ; Quang, L; Soparattanapaisarn, N; Inoue, T; Wang, CL; Huang, MJ; Yang, JCH; Cobo, M; Oezgueroglu, M; Casarini, I; Khiem, DV; Sriuranpong, V; Cronemberger, E; Takahashi, T; Runglodvatana, Y; Chen, M; Huang, XN; Grainger, E; Ghiorghiu, D; van der Gronde, T; Ramalingam, SS
View PubMed
-
TRANSL CANCER RES 2024 10.21037/tcr-23-2188
Machine learning prediction of the case-fatality of COVID-19 and risk factors for adverse outcomes in patients with non-small cell lung cancer
Jung, YJ; Ahn, J; Park, S; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Cho, SY; Jung, HA
View PubMed
-
NEURO-ONCOLOGY 2024 10.1093/neuonc/noae103
Leptomeningeal metastases from solid tumors: A Society for Neuro-Oncology and American Society of Clinical Oncology consensus review on clinical management and future directions
Wilcox, JA; Chukwueke, UN; Ahn, MJ; Aizer, AA; Bale, TA; Brandsma, D; Brastianos, PK; Chang, S; Daras, M; Forsyth, P; Garzia, L; Glantz, M; Oliva, ICG; Kumthekar, P; Le Rhun, E; Nagpal, S; O'Brien, B; Pentsova, E; Lee, EQ; Remsik, J; Ruda, R; Smalley, I; Taylor, MD; Weller, M; Wefel, J; Yang, JT; Young, RJ; Wen, PY; Boire, AA
View PubMed
-
CLIN LUNG CANCER 2024 10.1016/j.cllc.2023.12.010
STAR-121: A Phase III Randomized Study of Domvanalimab and Zimberelimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Untreated Metastatic Non-Small Cell Lung Cancer With No Actionable Gene Alterations
Rodriguez-Abreu, D; Bosch-Barrera, J; Gray, JE; Ahn, MJ; Johnson, M; Yu, XW; Mohammad, S; Chen, XY; Todd, T; Kim, J; Reck, M
View PubMed
-
J CLIN ONCOL 2024 10.1200/JCO.23.01891
Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04)
Park, S; Kim, TM; Han, JY; Lee, GW; Shim, BY; Lee, YG; Kim, SW; Kim, IH; Lee, S; Kim, YJ; Park, JH; Park, SG; Lee, KH; Kang, EJ; Kim, JW; Shin, SH; Ock, CY; Nam, BH; Lee, J; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ
View PubMed
-
BRIT J CANCER 2024 10.1038/s41416-024-02615-9
Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION
Kato, T; Yang, JCH; Ahn, MJ; Sakai, H; Morise, M; Chen, YM; Han, JY; Yang, JJ; Zhao, J; Hsia, TC; Berghoff, K; Bruns, R; Vioix, H; Lang, S; Johne, A; Le, XN; Paik, PK
View PubMed
-
LUNG CANCER 2024 10.1016/j.lungcan.2024.107530
Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III non-small-cell lung cancer: Results from the phase 1 CLOVER study
Kim, DW; Cho, BC; Pachipala, K; Kim, SW; Wang, CL; Chang, GC; Ahn, MJ; Alvarez, R; Chiu, CH; Trigo, J; Estival, A; Karam, SD; O'Brien, C; Gowda, H; Jiang, HY; Bauman, JE
View PubMed
-
LUNG CANCER 2024 10.1016/j.lungcan.2024.107509
Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201
Cho, BC; Han, JY; Lee, KH; Lee, YG; Kim, DW; Min, YJ; Kim, SW; Cho, EK; Kim, JH; Lee, GW; Lee, SS; Lee, NM; Wang, JY; Park, H; Ahn, MJ
View PubMed
-
LUNG CANCER 2024 10.1016/j.lungcan.2024.107536
Survival benefit in EGFR-wild and ALK negative NSCLC patients who participate in clinical trials compared to standard-of-care: Propensity-matched analysis
Jung, HA; Park, B; Park, S; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ
View PubMed
-
CANCER IMMUNOL IMMUN 2024 10.1007/s00262-024-03643-3
Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma
Seiwert, TY; Wildsmith, S; Fayette, J; Harrington, K; Gillison, M; Ahn, MJ; Takahashi, S; Weiss, J; Machiels, JP; Baxi, S; Baker, V; Evans, B; Morsli, N; Walker, J; Real, K; L'Hernault, A; Psyrri, A
View PubMed
-
EBIOMEDICINE 2024 10.1016/j.ebiom.2024.105062
Comprehensive analysis of transcription factor-based molecular subtypes and their correlation to clinical outcomes in small-cell lung cancer
Park, S; Hong, TH; Hwang, S; Heeke, S; Gay, CM; Kim, J; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Cho, JH; Choi, YS; Kim, J; Shim, YM; Kim, HK; Byers, LA; Heymach, JV; Choi, YL; Lee, SH; Park, K
View PubMed
-
INT J STROKE 2024 10.1177/17474930241239266
Edoxaban for the treatment of hypercoagulability and cerebral thromboembolism associated with cancer: A randomized clinical trial of biomarker targets
Chung, JW; Hwang, J; Kim, HJ; Seo, WK; Ahn, MJ; Saver, JL; Bang, OY
View PubMed
-
TRANSL LUNG CANCER R 2024 10.21037/tlcr-23-479
Predicting disease recurrence in limited disease small cell lung cancer using cell-free DNA-based mutation and fragmentome analyses
Park, S; Kang, JK; Lee, N; Lee, SH; Kim, HP; Kim, SY; Kim, TY; Kim, H; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K
View PubMed
-
J THORAC ONCOL 2024 10.1016/j.jtho.2023.09.1452
Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study
Vokes, EE; Mornex, F; Sezer, A; Cheng, Y; Fang, J; Baz, DV; Cil, T; Adjei, AA; Ahn, MJ; Barlesi, F; Felip, E; Garon, EB; Audhuy, F; Ito, R; Sato, M; Eggleton, SP; Martin, CM; Reck, M; Robinson, CG; Paz-Ares, L
View PubMed
-
FUTURE ONCOL 2024 10.2217/fon-2023-0859
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer
Riely, GJ; Smit, EF; Ahn, MJ; Felip, E; Ramalingam, SS; Tsao, A; Johnson, M; Gelsomino, F; Esper, R; Nadal, E; Offin, M; Provencio, M; Clarke, J; Hussein, M; Otterson, GA; Dagogo-Jack, I; Goldman, JW; Morgensztern, D; Alcasid, A; Usari, T; Wissel, P; Wilner, K; Pathan, N; Tonkovyd, S; Johnson, BE
View PubMed
-
CANCER RES TREAT 2024 10.4143/crt.2023.433
A Phase II Trial of Nintedanib in Patients with Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma: In-Depth Analysis of Nintedanib Arm from the KCSG HN 15-16 TRIUMPH Trial
Kim, KH; Lim, SM; Ahn, HK; Lee, YG; Lee, KW; Ahn, MJ; Keam, B; Kim, HR; Lee, HW; An, HJ; Kim, JS
View PubMed
-
CANCER RES TREAT 2024 10.4143/crt.2023.461
First-Line Alectinib vs. Brigatinib in Advanced Non-Small Cell Lung Cancer with ALKRearrangement: Real-World Data
Jeon, Y; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ
View PubMed
-
TRANSL LUNG CANCER R 2024 10.21037/tlcr-23-633
Machine learning model for circulating tumor DNA detection in chronic obstructive pulmonary disease patients with lung cancer
Shin, SH; Cha, S; Lee, HY; Shin, SH; Kim, YJ; Park, D; Han, KY; Oh, YJ; Park, WY; Ahn, MJ; Kim, H; Won, HH; Park, HY
View PubMed
-
J PERS MED 2024 10.3390/jpm14010071
Prognostic Value of Radiomic Analysis Using Pre- and Post-Treatment 18F-FDG-PET/CT in Patients with Laryngeal Cancer and Hypopharyngeal Cancer
Choi, JH; Choi, JY; Woo, SK; Moon, JE; Lim, CH; Park, SB; Seo, S; Ahn, YC; Ahn, MJ; Moon, SH; Park, JM
View PubMed
-
THYROID 2024 10.1089/thy.2023.0363
Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study
Subbiah, V; Hu, M; Mansfield, AS; Taylor, MH; Schuler, M; Zhu, VW; Hadoux, J; Curigliano, G; Wirth, L; Gainor, JF; Alonso, G; Adkins, D; Godbert, Y; Ahn, MJ; Cassier, PA; Cho, BC; Lin, CC; Zalutskaya, A; Barata, T; Trask, P; Scalori, A; Bordogna, W; Heinzmann, S; Brose, MS
View PubMed
-
CANCER-AM CANCER SOC 2024 10.1002/cncr.35175
Immune checkpoint inhibitor use and the incidence of hepatitis B virus reactivation or immune-related hepatitis in non-small cell lung cancer patients with chronic hepatitis B
Hong, J; Lee, J; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Sinn, DH; Ahn, MJ
View PubMed
-
CANCER RES TREAT 2024 10.4143/crt.2023.453
Lazertinib versus Gefitinib as First-Line Treatment for EGFR-Mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset
Lee, KH; Cho, BC; Ahn, MJ; Lee, YG; Lee, Y; Lee, JS; Kim, JH; Min, YJ; Lee, GW; Lee, SS; Lee, KH; Ko, YH; Shim, BY; Kim, SW; Shin, SW; Choi, JH; Kim, DW; Cho, EK; Park, KU; Kim, JS; Chun, SH; Wang, J; Choi, S; Kang, JH
View PubMed
-
J THORAC ONCOL 2023 10.1016/j.jtho.2023.08.018
Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial
Cho, BC; Lee, JS; Wu, YL; Cicin, I; Dols, MC; Ahn, MJ; Cuppens, K; Veillon, R; Nadal, E; Dias, JM; Martin, C; Reck, M; Garon, EB; Felip, E; Paz-Ares, L; Mornex, F; Vokes, EE; Adjei, AA; Robinson, C; Sato, M; Vugmeyster, Y; Machl, A; Audhuy, F; Chaudhary, S; Barlesi, F
View PubMed
-
J THORAC ONCOL 2023 10.1016/j.jtho.2023.08.010
Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial
Yang, JCH; Liu, GF; Lu, S; He, JX; Burotto, M; Ahn, MJ; Kim, DW; Liu, XQ; Zhao, YQ; Vincent, S; Yin, JN; Ma, X; Lin, HM; Popat, S
View PubMed
-
ORAL ONCOL 2023 10.1016/j.oraloncology.2023.106587
Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040) : Subgroup analysis by pattern of disease recurrence
Harrington, KJ; Cohen, EEW; Soulières, D; Dinis, J; Licitra, L; Ahn, MJ; Soria, A; Machiels, JP; Mach, N; Mehra, R; Burtness, B; Swaby, RF; Lin, J; Ge, J; Lerman, N; Le Tourneau, C
View PubMed
-
ESMO OPEN 2023 10.1016/j.esmoop.2023.102068
Dacomitinib in EGFR-mutant non-small-cell lung cancer with brain metastasis: a single-arm, phase II study
Jung, HA; Park, S; Lee, SH; Ahn, JS; Ahn, MJ; Sun, JM
View PubMed
-
TRANSL LUNG CANCER R 2023 10.21037/tlcr-23-643
Effectiveness and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in non-small cell lung cancer (NSCLC)
Choi, DH; Jung, HA; Park, S; Sun, JM; Ahn, JS; Ahn, MJ; Lee, SH
View PubMed
-
J CLIN ONCOL 2023 10.1200/JCO.23.01361
Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial
Goto, K; Goto, Y; Kubo, T; Ninomiya, K; Kim, SW; Planchard, D; Ahn, MJ; Smit, EF; de Langen, AJ; Pérol, M; Pons-Tostivint, E; Novello, S; Hayashi, H; Shimizu, J; Kim, DW; Kuo, CH; Yang, JCH; Pereira, K; Cheng, FC; Taguchi, A; Cheng, YK; Feng, WQ; Tsuchihashi, Z; Jänne, PA
View PubMed
-
CANCERS 2023 10.3390/cancers15225450
Real-World Outcomes of Immunotherapy in Second- or Later-Line Non-Small Cell Lung Cancer with Actionable Genetic Alterations
Jun, S; Park, S; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Cho, J; Jung, HA
View PubMed
-
J THORAC ONCOL 2023 10.1016/j.jtho.2023.06.013
Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study
Ahn, MJ; Bondarenko, I; Kalinka, E; Cho, BC; Sugawara, S; Galffy, G; Shim, BY; Kislov, N; Nagarkar, R; Demedts, I; Gans, SJM; Oliva, DM; Stewart, R; Lai, ZW; Mann, H; Shi, XJ; Hussein, M
View PubMed
-
CLIN CANCER RES 2023 10.1158/1078-0432.CCR-23-1030
A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma
Hanna, GJ; Ahn, MJ; Muzaffar, J; Keam, B; Bowles, DW; Wong, DJ; Ho, AL; Kim, SB; Worden, F; Yun, TK; Meng, XZ; Van Tornout, JM; Conlan, MG; Kang, H
View PubMed
-
J THORAC ONCOL 2023 10.1016/j.jtho.2023.08.017
Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis
Soo, RA; Cho, BC; Kim, JH; Ahn, MJ; Lee, KH; Zimina, A; Orlov, S; Bondarenko, I; Lee, YG; Lim, YN; Lee, SS; Lee, KH; Pang, YK; Fong, CH; Kang, JH; Lim, CS; Danchaivijitr, P; Kilickap, S; Yang, JCH; Arslan, C; Lee, HA; Park, SN; Cicin, I
View PubMed
-
CANCERS 2023 10.3390/cancers15204999
A Phase II Study of Osimertinib in Patients with Advanced-Stage Non-Small Cell Lung Cancer following Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Therapy with EGFR and T790M Mutations Detected in Plasma Circulating Tumour DNA (PLASMA Study)
Ang, YLE; Zhao, XT; Reungwetwattana, T; Cho, BC; Liao, BC; Yeung, R; Loong, HH; Kim, DW; Yang, JCH; Lim, SM; Ahn, MJ; Lee, SH; Suwatanapongched, T; Kongchauy, K; Ou, QX; Yu, RY; Tai, BC; Goh, BC; Mok, TSK; Soo, RA
View PubMed
-
TARGET ONCOL 2023 10.1007/s11523-023-00997-z
A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Razak, ARA; Wang, HM; Chang, JY; Ahn, MJ; Munster, P; Blumenschein, G Jr; Solomon, B; Lim, DWT; Hong, RL; Pfister, D; Saba, NF; Lee, SH; van Herpen, C; Quadt, C; Bootle, D; Blumenstein, L; Demanse, D; Delord, JP
View PubMed
-
HEAD NECK-J SCI SPEC 2023 10.1002/hed.27537
Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as a predictive biomarker for axitinib in adenoid cystic carcinoma
Kim, DH; Lim, Y; Ock, CY; Park, G; Park, S; Song, H; Ma, MN; Mostafavi, M; Kang, EJ; Ahn, MJ; Lee, KW; Kwon, JH; Yang, YW; Choi, YH; Kim, MK; Ji, JH; Yun, TK; Kim, SB; Keam, B
View PubMed
-
CANCER RES TREAT 2023 10.4143/crt.2023.403
Expanded Access Program Pralsetinib in Advanced Non-Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement
Jeon, Y; Jung, HA; Park, S; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH
View PubMed
-
CANCER RES TREAT 2023 10.4143/crt.2023.502
Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Kim, H; Park, S; Jung, HA; Lee, SH; Park, K; Ahn, YC; Oh, D; Ahn, MJ
View PubMed
-
CANCER-AM CANCER SOC 2023 10.1002/cncr.35059
Biomarker-driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer
Park, S; Kim, YJ; Min, YJ; Mortimer, PGS; Kim, HJ; Smith, SA; Dean, E; Jung, HA; Sun, JM; Park, WY; Ahn, JS; Ahn, MJ; Lee, SH; Park, K
View PubMed
-
J THORAC ONCOL 2023 10.1016/j.jtho.2023.06.016
Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naive Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301
Reungwetwattana, T; Cho, BC; Lee, KH; Pang, YK; Fong, CH; Kang, JH; Lee, YG; Sen Lim, C; Danchaivijitr, P; Lim, YN; Lee, YJ; How, SH; Geater, S; Lee, SS; Min, YJ; Kim, JH; Lee, JS; Lee, GW; Soo, RA; Lee, SY; Choi, S; Ahn, MJ
View PubMed
-
LUNG CANCER 2023 10.1016/j.lungcan.2023.107293
KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing
Lim, TKH; Skoulidis, F; Kerr, KM; Ahn, MJ; Kapp, JR; Soares, FA; Yatabe, Y
View PubMed
-
NEW ENGL J MED 2023 10.1056/NEJMoa2307980
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer
Ahn, MJ; Cho, BC; Felip, E; Korantzis, I; Ohashi, K; Majem, M; Juan-Vidal, O; Handzhiev, S; Izumi, H; Lee, JS; Dziadziuszko, R; Wolf, J; Blackhall, F; Reck, M; Alvarez, JB; Hummel, HD; Dingemans, AMC; Sands, J; Akamatsu, H; Owonikoko, TK; Ramalingam, SS; Borghaei, H; Johnson, ML; Huang, S; Mukherjee, S; Minocha, M; Jiang, TY; Martinez, P; Anderson, ES; Paz-Ares, L
View PubMed
-
MEDICINE 2023 10.1097/MD.0000000000035387
Increasing discrepancy of MR imaging and CSF study in patients with leptomeningeal seeding from lung adenocarcinoma after targeted therapy using a tyrosine kinase inhibitor
Seong, M; Park, S; Kim, ST; Park, SG; Kim, Y; Cha, J; Kim, EY; Kim, HJ; Ahn, MJ
View PubMed
-
J THORAC ONCOL 2023 10.1016/j.jtho.2023.05.027
Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to IIIA EGFR-Mutant Non-Small Cell Lung Cancer
Jung, HA; Ku, BM; Kim, YJ; Park, S; Sun, JM; Lee, SH; Ahn, JS; Cho, JH; Kim, HK; Choi, YS; Choi, YL; Shin, SH; Jeong, BH; Um, SW; Kim, H; Kim, K; Ahn, MJ; Kim, J
View PubMed
-
J CLIN ONCOL 2023 10.1200/JCO.23.00515
Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301
Cho, BC; Ahn, MJ; Kang, JH; Soo, RA; Reungwetwattana, T; Yang, JCH; Cicin, I; Kim, DW; Wu, YL; Lu, S; Lee, KH; Pang, YK; Zimina, A; Fong, CH; Poddubskaya, E; Sezer, A; How, SH; Danchaivijitr, P; Kim, Y; Lim, Y; An, T; Lee, HA; Byun, HM; Zaric, B
View PubMed
-
CLIN CANCER RES 2023 10.1158/1078-0432.CCR-22-3146
Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA
Gray, JE; Ahn, MJ; Oxnard, GR; Shepherd, FA; Imamura, F; Cheng, Y; Okamoto, I; Cho, BC; Lin, MC; Wu, YL; Majem, M; Gautschi, O; Boyer, M; Bulusu, KC; Markovets, A; Barrett, JC; Hodge, R; Mckeown, A; Hartmaier, RJ; Chmielecki, J; Papadimitrakopoulou, VA; Ramalingam, SS
View PubMed
-
JAMA ONCOL 2023 10.1001/jamaoncol.2023.3867
Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors A Phase 1a/1b Nonrandomized Controlled Trial
Kim, TW; Bedard, PL; Lorusso, P; Gordon, MS; Bendell, J; Oh, D; Ahn, MJ; Garralda, E; D'Angelo, SP; Desai, J; Hodi, FS; Wainberg, Z; Delord, JP; Cassier, PA; Cervantes, A; Gil-Martin, M; Wu, B; Patil, NS; Jin, Y; Hoang, T; Mendus, D; Wen, X; Meng, R; Cho, BC
View PubMed
-
CANCERS 2023 10.3390/cancers15174380
Prognostic Significance of Volumetric Parameters Based on FDG PET/CT in Patients with Lung Adenocarcinoma Undergoing Curative Surgery
Lee, H; Choi, YL; Kim, HK; Choi, YS; Kim, H; Ahn, MJ; Pyo, HR; Choi, JY
View PubMed
-
TRANSL LUNG CANCER R 2023 10.21037/tlcr-23-160
Real-world clinical evidence of lazertinib use in acquired EGFR T790M mutated non-small cell lung cancer
Park, S; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Sun, JM
View PubMed
-
J CLIN ONCOL 2023 10.1200/JCO.23.00774
Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAF(V600)-Mutant Metastatic Non-Small-Cell Lung Cancer
Riely, GJ; Smit, EF; Ahn, MJ; Felip, E; Ramalingam, SS; Tsao, A; Johnson, M; Gelsomino, F; Esper, R; Nadal, E; Offin, M; Provencio, M; Clarke, J; Hussain, M; Otterson, GA; Dagogo-Jack, I; Goldman, JW; Morgensztern, D; Alcasid, A; Usari, T; Wissel, P; Wilner, K; Pathan, N; Tonkovyd, S; Johnson, BE
View PubMed
-
CANCERS 2023 10.3390/cancers15143540
Detection of Cancer Recurrence Using Systemic Inflammatory Markers and Machine Learning after Concurrent Chemoradiotherapy for Head and Neck Cancers
So, YK; Kim, Z; Cheong, TY; Chung, MJ; Baek, CH; Son, YI; Seok, J; Jung, YS; Ahn, MJ; Ahn, YC; Oh, D; Cho, BH; Chung, MK
View PubMed
-
NAT MED 2023 10.1038/s41591-023-02385-6
Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results
Gutierrez, M; Lam, WS; Hellmann, MD; Gubens, MA; Aggarwal, C; Tan, DSW; Felip, E; Chiu, JWY; Lee, JS; Yang, JCH; Garon, EB; Finocchiaro, G; Ahn, MJ; Luft, A; Landers, GA; Basso, A; Ma, H; Kobie, J; Palcza, J; Cristescu, R; Fong, L; Snyder, A; Yuan, JD; Herbst, RS
View PubMed
-
CANCER MED-US 2023 10.1002/cam4.6260
Safety and tolerability of first-line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinoma
Lee, DH; Kim, HR; Keam, B; Kato, K; Kuboki, Y; Gao, HY; Yovine, A; Robbins, SH; Ahn, MJ
View PubMed
-
J THORAC ONCOL 2023 10.1016/j.jtho.2023.03.024
Programmed Death-Ligand 1 Copy Number Alteration as an Adjunct Biomarker of Response to Immunotherapy in Advanced NSCLC
Hong, TH; Bang, YH; Joe, CY; Hwang, S; Lee, B; Lee, N; Park, S; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Choi, YL; Lee, SH
View PubMed
-
INT J CANCER 2023 10.1002/ijc.34622
A phase Ia/Ib study of novel anti-ErbB3 monoclonal antibody, barecetamab (ISU104) in refractory solid cancers and monotherapy or in combination with cetuximab in recurrent or metastatic head and neck cancer
Seo, S; Keam, B; Shin, SH; Chae, YS; Kim, TM; Park, LC; Hong, SB; Ahn, MJ; Kim, SB
View PubMed
-
JAMA ONCOL 2023 10.1001/jamaoncol.2023.1962
Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial
Mazieres, J; Paik, PK; Garassino, MC; Le, XN; Sakai, H; Veillon, R; Smit, EF; Cortot, AB; Raskin, J; Viteri, S; Wu, YL; Yang, JCH; Ahn, MJ; Ma, R; Zhao, J; O'Brate, A; Berghoff, K; Bruns, R; Otto, G; Johne, A; Felip, E; Thomas, M
View PubMed
-
CANCER-AM CANCER SOC 2023 10.1002/cncr.34892
A phase 2 multicenter study of docetaxel-PM and trastuzumab-pkrb combination therapy in recurrent or metastatic salivary gland carcinomas
Lee, J; Park, S; Jung, HA; Lee, SH; Seo, S; Kim, SB; Kim, JW; Lee, KW; Kang, EJ; Kim, JW; Choi, YJ; Shim, BY; An, HJ; Park, LC; Shin, SH; Kim, JJ; Oh, SY; Kim, MK; Ahn, MJ
View PubMed
-
SCI REP-UK 2023 10.1038/s41598-023-35582-x
The prognostic value of radiomic features from pre- and post-treatment F-18-FDG PET imaging in patients with nasopharyngeal carcinoma
Kim, SJ; Choi, JY; Ahn, YC; Ahn, MJ; Moon, SH
View PubMed
-
J STROKE 2023 10.5853/jos.2022.02327
Circulating Extracellular-Vesicle-Incorporated MicroRNAs as Potential Biomarkers for Ischemic Stroke in Patients With Cancer
Bang, OY; Kim, EH; Oh, MJ; Yoo, J; Oh, GS; Chung, JW; Seo, WK; Kim, GM; Ahn, MJ; Yang, SW; OASIS-CANC Study
View PubMed
-
ESMO OPEN 2023 10.1016/j.esmoop.2023.101173
A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naive, cisplatin-ineligible urothelial cancer
Galffy, G; Lugowska, I; Poddubskaya, EV; Cho, BC; Ahn, MJ; Han, JY; Su, WC; Hauke, RJ; Dyar, SH; Lee, DH; Serwatowski, P; Estelles, DL; Holden, VR; Kim, YJ; Vladimirov, V; Horvath, Z; Ghose, A; Goldman, A; di Pietro, A; Wang, J; Murphy, DA; Alhadab, A; Laskov, M
View PubMed
-
ELIFE 2023 10.7554/eLife.81646
Noncovalent antibody catenation on a target surface greatly increases the antigen-binding avidity
Song, J; Jeong, BS; Kim, SW; Im, SB; Kim, S; Lai, CJ; Cho, W; Jung, JU; Ahn, MJ; Oh, BH; Ng, T
View PubMed
-
MODERN PATHOL 2023 10.1016/j.modpat.2023.100184
Whole-Section Landscape Analysis of Molecular Subtypes in Curatively Resected Small Cell Lung Cancer: Clinicopathologic Features and Prognostic Significance
Hwang, S; Hong, TH; Kim, HK; Choi, YS; Zo, JI; Shim, YM; Han, J; Ahn, YC; Pyo, H; Noh, JM; Lee, HY; Kim, HJ; Park, S; Ahn, MJ; Park, K; Lee, SH; Choi, YL; Kim, J
View PubMed
-
ADV SCI 2023 10.1002/advs.202204378
Intracellular Adhesion Molecule-1 Improves Responsiveness to Immune Checkpoint Inhibitor by Activating CD8(+) T Cells
Lee, SH; Kim, Y; Jeon, BN; Kim, G; Sohn, J; Yoon, Y; Kim, S; Kim, Y; Kim, H; Cha, HG; Lee, NE; Yang, HYS; Chung, JY; Jeong, AR; Kim, YY; Kim, SG; Seo, Y; Park, S; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, H; Yoon, KW
View PubMed
-
CANCER RES TREAT 2023 10.4143/crt.2022.388
EGFR Mutation-Positive Unresectable Stage III Non-Squamous Lung Cancer Is Associated with a High Incidence of Brain Metastasis
Kim, H; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ
View PubMed
-
CANCER RES TREAT 2023 10.4143/crt.2022.1344
The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non-Small Cell Lung Cancer
Jung, HA; Park, S; Lee, SH; Ahn, JS; Ahn, MJ; Sun, JM
View PubMed
-
CANCERS 2023 10.3390/cancers15072012
Radiomics Analysis of F-18-FDG PET/CT for Prognosis Prediction in Patients with Stage III Non-Small Cell Lung Cancer Undergoing Neoadjuvant Chemoradiation Therapy Followed by Surgery
Yoo, J; Lee, JH; Cheon, M; Kim, H; Choi, YS; Pyo, H; Ahn, MJ; Choi, JY
View PubMed
-
HISTOPATHOLOGY 2023 10.1111/his.14894
Different prognostic role of EGFR mutation according to the IASLC histological grade in patients with resected early-stage lung adenocarcinoma
Hong, TH; Hwang, S; Choi, YL; Lee, GEH; Park, S; Ahn, MJ; Lee, Y; Jeon, YJ; Lee, J; Shin, S; Park, SY; Cho, JH; Choi, YS; Kim, J; Shim, YM; Cho, JH; Kim, HK
View PubMed
-
J THORAC ONCOL 2023 10.1016/j.jtho.2022.10.021
Expert Consensus Recommendations on Biomarker Testing in Metastatic and Nonmetastatic NSCLC in Asia
Mitsudomi, T; Tan, D; Yang, JCH; Ahn, MJ; Batra, U; Cho, BC; Cornelio, G; Lim, T; Mok, T; Prabhash, K; Reungwetwattana, T; Ren, SX; Singh, N; Toyooka, S; Wu, YL; Yang, PC; Yatabe, Y
View PubMed
-
JAMA NETW OPEN 2023 10.1001/jamanetworkopen.2023.2002
Trends in Survival Rates of Non-Small Cell Lung Cancer With Use of Molecular Testing and Targeted Therapy in Korea, 2010-2020
Chi, SA; Yu, H; Choi, YL; Park, S; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Choi, DH; Kim, K; Jung, HA; Park, K
View PubMed
-
ANN ONCOL 2023 10.1016/j.annonc.2022.12.007
Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial
Chan, ATC; Lee, VHF; Hong, RL; Ahn, MJ; Chong, WQ; Kim, SB; Ho, GF; Caguioa, PB; Ngamphaiboon, N; Ho, C; Aziz, MASA; Ng, QS; Yen, CJ; Soparattanapaisarn, N; Ngan, RKC; Kho, SK; Tiambeng, MLA; Yun, T; Sriuranpong, V; Algazi, AP; Cheng, A; Massarelli, E; Swaby, RF; Saraf, S; Yuan, J; Siu, LL
View PubMed
-
CANCERS 2023 10.3390/cancers15041248
Prognostic Significance of the Post-Treatment Neutrophil-to-Lymphocyte Ratio in Pharyngeal Cancers Treated with Concurrent Chemoradiotherapy
Yun, JM; Chung, MK; Baek, CH; Son, YI; Ahn, MJ; Oh, D; Kim, KW; So, YK
View PubMed
-
ANN ONCOL 2023 10.1016/j.annonc.2022.12.008
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study
Psyrri, A; Fayette, J; Harrington, K; Gillison, M; Ahn, MJ; Takahashi, S; Weiss, J; Machiels, JP; Baxi, S; Vasilyev, A; Karpenko, A; Dvorkin, M; Hsieh, CY; Thungappa, SC; Segura, PP; Vynnychenko, I; Haddad, R; Kasper, S; Mauz, PS; Baker, V; He, P; Evans, B; Wildsmith, S; Olsson, RF; Yovine, A; Kurland, JF; Morsli, N; Seiwert, TY
View PubMed
-
NAT COMMUN 2023 10.1038/s41467-023-35962-x
Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial
Chmielecki, J; Mok, T; Wu, YL; Han, JY; Ahn, MJ; Ramalingam, SS; John, T; Okamoto, I; Yang, JCH; Shepherd, FA; Bulusu, KC; Laus, G; Collins, B; Barrett, JC; Hartmaier, RJ; Papadimitrakopoulou, V
View PubMed
-
J IMMUNOTHER CANCER 2023 10.1136/jitc-2022-005509
Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatment
Kim, H; Park, S; Han, KY; Lee, N; Kim, H; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Lee, SH; Park, WY
View PubMed
-
J THORAC ONCOL 2023 10.1016/j.jtho.2022.10.008
A Phase 2 Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumors (KCSG LU17-21)
Jung, HA; Kim, M; Kim, HS; Kim, JH; Choi, YH; Cho, J; Park, JH; Park, KU; Ku, BM; Park, S; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
View PubMed
-
CANCER RES TREAT 2023 10.4143/crt.2021.1603
Osimertinib Combined with Systemic Chemotherapy for EGFR Mutant, T790M-Negative, Non-Small Cell Lung Cancer Patients Who Develop Leptomeningeal Metastases with Extracranial Progression to Prior EGFR TKI
Kim, HR; Jo, H; Kim, H; Hong, J; Park, S; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ
View PubMed
-
CANCER DISCOV 2023 10.1158/2159-8290.CD-22-0586
Osimertinib plus Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON
Hartmaier, RJ; Markovets, AA; Ahn, MJ; Sequist, LV; Han, JY; Cho, BC; Yu, HA; Kim, SW; Yang, JCH; Lee, JS; Su, WC; Kowalski, DM; Orlov, S; Ren, S; Frewer, P; Ou, XL; Cross, DAE; Kurian, N; Cantarini, M; Janne, PA
View PubMed
-
TARGET ONCOL 2023 10.1007/s11523-022-00941-7
Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies
Popat, S; Ahn, MJ; Ekman, S; Leighl, NB; Ramalingam, SS; Reungwetwattana, T; Siva, S; Tsuboi, M; Wu, YL; Yang, JCH
View PubMed
-
SCI REP-UK 2023 10.1038/s41598-022-24875-2
Prognostic value of pretherapeutic FDG PET/CT in non-small cell lung cancer with pulmonary lymphangitic carcinomatosis
Park, YJ; Im, Y; Kwon, OJ; Han, J; Ahn, MJ; Kim, J; Um, SW; Choi, JY
View PubMed
-
INT J RADIAT ONCOL 2023 10.1016/j.ijrobp.2022.07.018
Association of T Cell Senescence with Radiation Pneumonitis in Patients with Non-small Cell Lung Cancer
Kim, KH; Pyo, H; Lee, H; Oh, D; Noh, JM; Ahn, YC; Kim, CG; Yoon, HI; Lee, J; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ku, BM; Shin, EC; Ahn, MJ
View PubMed
-
CANCER MED-US 2022 10.1002/cam4.5460
Transcriptional upregulation of CXCL13 is correlated with a favorable response to immune checkpoint inhibitors in lung adenocarcinoma
Park, S; Cha, H; Kim, HS; Lee, B; Kim, S; Kim, TM; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Park, WY; Lee, SH
View PubMed
-
J THORAC ONCOL 2022 10.1016/j.jtho.2022.08.018
Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2)
Ou, SHI; Nishio, M; Ahn, MJ; Mok, T; Barlesi, F; Zhou, CC; Felip, E; de Marinis, F; Kim, SW; Perol, M; Liu, G; Migliorino, MR; Kim, DW; Novello, S; Bearz, A; Garrido, P; Mazieres, J; Morabito, A; Lin, HM; Yang, H; Niu, HF; Zhang, PK; Kim, ES
View PubMed
-
CLIN LUNG CANCER 2022 10.1016/j.cllc.2022.07.012
Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations
Ahn, MJ; Mendoza, MJL; Pavlakis, N; Kato, T; Soo, RA; Kim, DW; Liam, CK; Hsia, TC; Lee, CK; Reungwetwattana, T; Geater, S; Chan, OSH; Prasongsook, N; Solomon, BJ; Nguyen, TTH; Kozuki, T; Yang, JCH; Wu, YL; Kam, TS; Tan, DSW; Yatabe, Y
View PubMed
-
CLIN LUNG CANCER 2022 10.1016/j.cllc.2022.07.008
Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK plus Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study
Ahn, MJ; Kim, HR; Yang, JCH; Han, JY; Li, JYC; Hochmair, MJ; Chang, GC; Delmonte, A; Lee, KH; Campelo, RG; Gridelli, C; Spira, AI; Califano, R; Griesinger, F; Ghosh, S; Felip, E; Kim, DW; Liu, YY; Zhang, PK; Popat, S; Camidge, DR
View PubMed
-
PLOS ONE 2022 10.1371/journal.pone.0274830
Prognostic value of FOXP3+regulatory T cells for patients with locally advanced oropharyngeal squamous cell carcinoma
Hur, JY; Ku, BM; Park, S; Jung, HA; Lee, SH; Ahn, MJ
View PubMed
-
CLIN CANCER RES 2022 10.1158/1078-0432.CCR-21-4329
Osimertinib plus Selumetinib in EGFR-Mutated Non-Small Cell Lung Cancer After Progression on EGFR-TKIs: A Phase Ib, Open-Label, Multicenter Trial (TATTON Part B)
Yang, JCH; Ohe, Y; Chiu, CH; Ou, XL; Cantarini, M; Janne, PA; Hartmaier, RJ; Ahn, MJ
View PubMed
-
ISCIENCE 2022 10.1016/j.isci.2022.105358
Cellular plasticity and immune microenvironment of malignant pleural effusion are associated with EGFR-TKI resistance in non-small-cell lung carcinoma
Jeong, HO; Lee, H; Kim, H; Jang, J; Kim, S; Hwang, T; Choi, DWY; Kim, HS; Lee, N; Lee, YM; Park, S; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SM; Lee, SH
View PubMed
-
CLIN CANCER RES 2022 10.1158/1078-0432.CCR-22-0879
Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC
Jung, HA; Lim, J; Choi, YL; Lee, SH; Joung, JG; Jeon, YJ; Choi, JW; Shin, S; Cho, JH; Kim, HK; Choi, YS; Zo, JI; Shim, YM; Park, S; Sun, JM; Ahn, JS; Ahn, MJ; Han, JH; Park, WY; Kim, J; Park, K
View PubMed
-
FRONT MED-LAUSANNE 2022 10.3389/fmed.2022.896494
Metabolic parameters on baseline F-18-FDG PET/CT are potential predictive biomarkers for immunotherapy in patients with head and neck squamous cell carcinoma
Kwon, HR; Cho, JH; Park, S; Lee, SH; Ahn, MJ; Choi, JY; Lee, KH; Jung, HA; Moon, SH
View PubMed
-
J THORAC ONCOL 2022 10.1016/j.jtho.2022.07.1141
A Response to the Letter to the Editor: Bevacizumab Plus Atezolizumab in Pretreated Progressive and Metastatic Non-Small Cell Lung Cancer
Lee, J; Ahn, MJ
View PubMed
-
CLIN CANCER RES 2022 10.1158/1078-0432.CCR-21-0985
Three-Year Follow-Up and Response-Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3)
Okada, M; Kato, K; Cho, BC; Takahashi, M; Lin, CY; Chin, K; Kadowaki, S; Ahn, MJ; Hamamoto, Y; Doki, Y; Yen, CC; Kubota, Y; Kim, SB; Hsu, CH; Holtved, E; Xynos, I; Matsumura, Y; Takazawa, A; Kitagawa, Y
View PubMed
-
CANCERS 2022 10.3390/cancers14153809
Prognostic Significance of Pseudotime from Texture Parameters of FDG PET/CT in Locally Advanced Non-Small-Cell Lung Cancer with Tri-Modality Therapy
Lee, H; Kim, H; Choi, YS; Pyo, HR; Ahn, MJ; Choi, JY
View PubMed
-
CANCER RES TREAT 2022 10.4143/crt.2021.1019
A Single-Arm, Prospective, Phase II Study of Cisplatin Plus Weekly Docetaxel as First-Line Therapy in Patients with Metastatic or Recurrent Salivary Gland Cancer
Kim, HR; Lee, SJ; Park, S; Jung, HA; Lee, SH; Jeong, HS; Chung, MK; Ahn, MJ
View PubMed
-
CANCER RES TREAT 2022 10.4143/crt.2021.822
The Impact of EGFR Tyrosine Kinase Inhibitor on the Natural Course of Concurrent Subsolid Nodules in Patients with Non-Small Cell Lung Cancer
Kang, N; Kim, KH; Jeong, BH; Lee, K; Kim, H; Kwon, OJ; Ahn, MJ; Cho, J; Lee, HY; Um, SW
View PubMed
-
J THORAC ONCOL 2022 10.1016/j.jtho.2022.04.001
Bevacizumab Plus Atezolizumab After Progression on Atezolizumab Monotherapy in Pretreated Patients With NSCLC: An Open-Label, Two-Stage, Phase 2 Trial
Lee, J; Koh, J; Kim, HK; Hong, S; Kim, K; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
View PubMed
-
J CLIN ONCOL 2022 10.1200/JCO.21.02010
Artificial Intelligence-Powered Spatial Analysis of Tumor-Infiltrating Lymphocytes as Complementary Biomarker for Immune Checkpoint Inhibition in Non-Small-Cell Lung Cancer
Park, S; Ock, CY; Kim, H; Pereira, S; Park, S; Ma, M; Choi, S; Kim, S; Shin, S; Aum, BJ; Paeng, K; Yoo, D; Cha, H; Park, S; Suh, KJ; Jung, HA; Kim, SH; Kim, YJ; Sun, JM; Chung, JH; Ahn, JS; Ahn, MJ; Lee, JS; Park, K; Song, SY; Bang, YJ; Choi, YL; Mok, TS; Lee, SH
View PubMed
-
CLIN CANCER RES 2022 10.1158/1078-0432.CCR-21-3646
Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study
Jung, HA; Park, S; Choi, YL; Lee, SH; Ahn, JS; Ahn, MJ; Sun, JM
View PubMed
-
INT J RADIAT ONCOL 2022 10.1016/j.ijrobp.2022.02.003
Dynamics of Circulating Immune Cells During Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer Support Earlier Administration of Anti-PD-1/PD-L1
Kim, KH; Pyo, H; Lee, H; Oh, D; Noh, JM; Ahn, YC; Yoon, HI; Moon, H; Lee, J; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ku, BM; Ahn, MJ; Shin, EC
View PubMed
-
EUR J CANCER 2022 10.1016/j.ejca.2022.03.034
Durvalumab with chemoradiotherapy for limited-stage small-cell lung cancer
Park, S; Noh, JM; Choi, YL; Chi, SA; Kim, K; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Sun, JM
View PubMed
-
ANN ONCOL 2022 10.1016/j.annonc.2022.02.003
ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer
Passaro, A; Leighl, N; Blackhall, F; Popat, S; Kerr, K; Ahn, MJ; Arcila, ME; Arrieta, O; Planchard, D; de Marinis, F; Dingemans, AM; Dziadziuszko, R; Faivre-Finn, C; Feldman, J; Felip, E; Curigliano, G; Herbst, R; Janne, PA; John, T; Mitsudomi, T; Mok, T; Normanno, N; Paz-Ares, L; Ramalingam, S; Sequist, L; Vansteenkiste, J; Wistuba, II; Wolf, J; Wu, YL; Yang, SR; Yang, JCH; Yatabe, Y; Pentheroudakis, G; Peters, S
View PubMed
-
J THORAC ONCOL 2022 10.1016/j.jtho.2022.01.012
Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial
Ahn, MJ; Cho, BC; Ou, XL; Walding, A; Dymond, AW; Ren, S; Cantarini, M; Janne, PA
View PubMed
-
CANCER MED-US 2022 10.1002/cam4.4663
Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors
Kwon, M; Ku, BM; Olsen, S; Park, S; Lefterova, M; Odegaard, J; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
View PubMed
-
CANCERS 2022 10.3390/cancers14081987
Predictive Value of F-18-FDG PET/CT Using Machine Learning for Pathological Response to Neoadjuvant Concurrent Chemoradiotherapy in Patients with Stage III Non-Small Cell Lung Cancer
Yoo, J; Lee, J; Cheon, M; Woo, SK; Ahn, MJ; Pyo, HR; Choi, YS; Han, JH; Choi, JY
View PubMed
-
CLIN CANCER RES 2022 10.1158/1078-0432.CCR-21-3597
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors
Demetri, GD; De Braud, F; Drilon, A; Siena, S; Patel, MR; Cho, BC; Liu, SV; Ahn, MJ; Chiu, CH; Lin, JJ; Goto, K; Lee, J; Bazhenova, L; John, T; Fakih, M; Chawla, SP; Dziadziuszko, R; Seto, T; Heinzmann, S; Pitcher, B; Chen, D; Wilson, TR; Rolfo, C
View PubMed
-
CANCER-AM CANCER SOC 2022 10.1002/cncr.34176
Durvalumab and tremelimumab with definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma
Park, S; Oh, D; Choi, YL; Chi, SA; Kim, K; Ahn, MJ; Sun, JM
View PubMed
-
J THORAC ONCOL 2022 10.1016/j.jtho.2021.11.025
A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors
Cho, BC; Han, JY; Kim, SW; Lee, KH; Cho, EK; Lee, YG; Kim, DW; Kim, JH; Lee, GW; Lee, JS; Shim, BY; Kim, JS; Chun, SH; Lee, SS; Kim, HR; Hong, MH; Ahn, JS; Sun, JM; Lee, Y; Lee, DH; Kang, JA; Lee, N; Kwon, MJ; Espenschied, C; Yablonovitch, A; Ahn, MJ
View PubMed
-
CANCERS 2022 10.3390/cancers14030632
Clinical Value of Surveillance F-18-fluorodeoxyglucose PET/CT for Detecting Unsuspected Recurrence or Second Primary Cancer in Non-Small Cell Lung Cancer after Curative Therapy
Lim, CH; Park, SB; Kim, HK; Choi, YS; Kim, J; Ahn, YC; Ahn, MJ; Choi, JY
View PubMed
-
ONCOLOGY-BASEL 2022 10.1159/000516813
Role of Circulating Tumor DNA Profiling in Patients with Non-Small Cell Lung Cancer Treated with EGFR Inhibitor
Ku, BM; Kim, YJ; Park, D; Lee, SH; Ahn, JS; Park, K; Ahn, MJ; Sun, JM
View PubMed
-
J CLIN MED 2022 10.3390/jcm11041144
Clinical Utility of Plasma Cell-Free DNA EGFR Mutation Analysis in Treatment-Naive Stage IV Non-Small Cell Lung Cancer Patients
Kim, BG; Jang, JH; Kim, JW; Shin, SH; Jeong, BH; Lee, K; Kim, H; Kwon, OJ; Ahn, MJ; Um, SW
View PubMed
-
ESMO OPEN 2022 10.1016/j.esmoop.2022.100385
Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study
Park, S; Sun, JM; Choi, YL; Oh, D; Kim, HK; Lee, T; Chi, SA; Lee, SH; Choi, YS; Jung, SH; Ahn, MJ; Ahn, YC; Park, K; Shim, YM
View PubMed
-
ANN ONCOL 2022 10.1016/j.annonc.2021.11.002
First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer
Niu, J; Maurice-Dror, C; Lee, DH; Kim, DW; Nagrial, A; Voskoboynik, M; Chung, HC; Mileham, K; Vaishampayan, U; Rasco, D; Golan, T; Bauer, TM; Jimeno, A; Chung, V; Chartash, E; Lala, M; Chen, Q; Healy, JA; Ahn, MJ
View PubMed
-
CANCER RES TREAT 2022 10.4143/crt.2021.306
Long-term Survival in Non-Small Cell Lung Cancer Patients with Metachronous Brain-Only Oligorecurrence Who Underwent Definitive Treatment
Kim, H; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
View PubMed
-
INVEST NEW DRUG 2022 10.1007/s10637-021-01121-6
ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non-small cell lung cancer
Ku, BM; Heo, JY; Kim, J; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
View PubMed
-
J CLIN MED 2022 10.3390/jcm11010123
The Role of Factor Xa-Independent Pathway and Anticoagulant Therapies in Cancer-Related Stroke
Kim, HJ; Chung, JW; Bang, OY; Cho, YH; Lim, YJ; Hwang, J; Seo, WK; Kim, GM; Kim, HJ; Ahn, MJ
View PubMed
-
FUTURE ONCOL 2021 10.2217/fon-2021-1250
Encorafenib plus binimetinib in patients with BRAF(V)(600)-mutant non-small cell lung cancer: Phase II PHAROS study design
Riely, GJ; Ahn, MJ; Felip, E; Ramalingam, SS; Smit, EF; Tsao, AS; Alcasid, A; Usari, T; Wissel, PS; Wilner, KD; Johnson, BE
View PubMed
-
J THORAC ONCOL 2021 10.1016/j.jtho.2021.07.035
Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial
Camidge, DR; Kim, HR; Ahn, MJ; Yang, JCH; Han, JY; Hochmair, MJ; Lee, KH; Delmonte, A; Campelo, DHMRG; Kim, DW; Griesinger, F; Felip, E; Califano, R; Spira, AI; Gettinger, SN; Tiseo, M; Lin, HMM; Liu, YY; Vranceanu, F; Niu, HF; Zhang, PK; Popat, S
View PubMed
-
J THORAC ONCOL 2021 10.1016/j.jtho.2021.09.007
Lung Cancer in Korea
Park, S; Choi, CM; Hwang, SS; Choi, YL; Kim, HY; Kim, YC; Kim, YT; Lee, HY; Song, SY; Ahn, MJ
View PubMed
-
EUR J CANCER 2021 10.1016/j.ejca.2021.09.037
Extrapulmonary tuberculosis in patients with RET fusion-positive non-small cell lung cancer treated with pralsetinib: A Korean single-centre compassionate use experience
Lee, YP; Jeong, BH; Eun, Y; Kang, CI; Park, S; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM
View PubMed
-
TRANSL LUNG CANCER R 2021 10.21037/tlcr-21-691
Molecular subtypes of small cell lung cancer transformed from adenocarcinoma after EGFR tyrosine kinase inhibitor treatment
Hwang, S; Hong, TH; Park, S; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Choi, YL; Lee, SH
View PubMed
-
TRANSL LUNG CANCER R 2021 10.21037/tlcr-21-677
Prognosis of pulmonary lymphangitic carcinomatosis in patients with non-small cell lung cancer
Im, Y; Lee, H; Lee, HY; Baek, SY; Jeong, BH; Lee, K; Kim, H; Kwon, OJ; Han, J; Lee, KS; Ahn, MJ; Kim, J; Um, SW
View PubMed
-
CANCER-AM CANCER SOC 2021 10.1002/cncr.33984
Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11)
Kim, H; Kim, DW; Kim, M; Lee, Y; Ahn, HK; Cho, JH; Kim, I; Lee, YG; Shin, SH; Park, SE; Jung, J; Kang, EJ; Ahn, MJ
View PubMed
-
CLIN CANCER RES 2021 10.1158/1078-0432.CCR-21-1061
Randomized Phase II Study of Axitinib versus Observation in Patients with Recurred or Metastatic Adenoid Cystic Carcinoma
Kang, EJ; Ahn, MJ; Ock, CY; Lee, KW; Kwon, JH; Yang, Y; Choi, YH; Kim, MK; Ji, JH; Yun, T; Nam, BH; Kim, SB; Keam, B
View PubMed
-
BIOMEDICINES 2021 10.3390/biomedicines9091076
Complementary Use of Presepsin with the Sepsis-3 Criteria Improved Identification of High-Risk Patients with Suspected Sepsis
Park, JE; Lee, B; Yoon, SJ; Park, CM; Jung, CW; Ahn, MJ; Park, HD; Hwang, SY; Shin, TG; Kang, ES
View PubMed
-
TRANSL LUNG CANCER R 2021 10.21037/tlcr-21-531
Real-time autOmatically updated data warehOuse in healThcare (ROOT): an innovative and automated data collection system
Jung, HA; Jeong, O; Chang, DK; Park, S; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Park, K
View PubMed
-
CANCER TREAT REV 2021 10.1016/j.ctrv.2021.102291
Brain metastases in patients with oncogenic-driven non-small cell lung cancer: Pros and cons for early radiotherapy
Lee, J; Ahn, MJ
View PubMed
-
LUNG CANCER 2021 10.1016/j.lungcan.2021.07.009
Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer
Cho, BC; Yoh, K; Perets, R; Nagrial, A; Spigel, DR; Gutierrez, M; Kim, DW; Kotasek, D; Rasco, D; Niu, JX; Satouchi, M; Ahn, MJ; Lee, DH; Maurice-Dror, C; Siddiqi, S; Ren, YX; Altura, RA; Bar, J
View PubMed
-
CANCER RES TREAT 2021 10.4143/crt.2020.824
Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12
Lee, YG; Chang, H; Keam, B; Chun, SH; Park, J; Park, KU; Shin, SH; An, HJ; Lee, KE; Lee, KW; Kim, HR; Kim, SB; Ahn, MJ; Hwang, IG
View PubMed
-
NANOMED-NANOTECHNOL 2021 10.1016/j.nano.2021.102415
Therapeutic efficacy of cancer vaccine adjuvanted with nanoemulsion loaded with TLR7/8 agonist in lung cancer model
Koh, J; Kim, S; Lee, SN; Kim, SY; Kim, JE; Lee, KY; Kim, MS; Heo, JY; Park, YM; Ku, BM; Sun, JM; Lee, SH; Ahn, JS; Park, K; Yang, S; Ha, SJ; Lim, YT; Ahn, MJ
View PubMed
-
CLIN LUNG CANCER 2021 10.1016/j.cllc.2021.02.010
Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC)
Garon, EB; Cho, BC; Reinmuth, N; Lee, KH; Luft, A; Ahn, MJ; Robinet, G; Le Moulec, S; Natale, R; Schneider, J; Shepherd, FA; Garassino, MC; Geater, SL; Szekely, ZP; Ngoc, TV; Liu, F; Scheuring, U; Patel, N; Peters, S; Rizvi, NA
View PubMed
-
BMB REP 2021 10.5483/BMBRep.2021.54.7.045
Paired analysis of tumor mutation burden calculated by targeted deep sequencing panel and whole exome sequencing in non-small cell lung cancer
Park, S; Lee, C; Ku, BM; Kim, M; Park, WY; Kim, NKD; Ahn, MJ
View PubMed
-
ESMO OPEN 2021 10.1016/j.esmoop.2021.100113
Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours
Paz-Ares1, L; Barlesi, F; Siena, S; Ahn, MJ; Drilon, A; Conley, A; Rolfo, C; Wolf, J; Seto, T; Doebele, R; Kapre, A; Chen, D; McCallum, S; Osborne, S; Demetri, G
View PubMed
-
J THORAC ONCOL 2021 10.1016/j.jtho.2020.12.002
Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations
Passaro1, A; Mok, T; Peters, S; Popat, S; Ahn, MJ; de Marinis, F
View PubMed
-
PROCESSES 2021 10.3390/pr9050792
Comprehensive Analysis of Mutation-Based and Expressed Genes-Based Pathways in Head and Neck Squamous Cell Carcinoma
Keam1, B; Park, JY; Kim, JP; Kim, GD; Yu, YS; Cho, SH; Kim, S; Ahn, HK; Chun, SH; Kwon, JH; Yun, T; Kim, JW; Kim, JE; Ahn, MJ; Kim, JH; Yun, HJ
View PubMed
-
CANCER 2021 10.1002/cncr.33571
High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean lung liquid versus invasive biopsy program
Park1, S; Olsen, S; Ku, BM; Lee, MS; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Choi, YL; Ahn, MJ
View PubMed
-
J CLIN ONCOL 2021 10.1200/JCO.20.03025
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer
Dziadziuszko1, R; Krebs, MG; De Braud, F; Siena, S; Drilon, A; Doebele, RC; Patel, MR; Cho, BC; Liu, SV; Ahn, MJ; Chiu, CH; Farago, AF; Lin, CC; Karapetis, CS; Li, YC; Day, Bm; Chen, D; Wilson, TR; Barlesi, F
View PubMed
-
KOREAN J INTERN MED 2021 10.3904/kjim.2019.161
Induction chemotherapy followed by concurrent chemoradiotherapy versus CCRT for locally advanced hypopharynx and base of tongue cancer
Lim1, SH; Sun, JM; Hong, J; Oh, D; Ahn, YC; Chung, MK; Jeong, HS; Son, YI; Ahn, MJ; Baek, CH; Park, K
View PubMed
-
ANN ONCOL 2021 10.1016/j.annonc.2020.11.020
Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer
Perets1, R; Bar, J; Rasco, DW; Ahn, MJ; Yoh, K; Kim, DW; Nagrial, A; Satouchi, M; Lee, DH; Spigel, DR; Kotasek, D; Gutierrez, M; Niu, J; Siddiqi, S; Li, X; Cyrus, J; Chackerian, A; Chain, A; Altura, RA; Cho, BC
View PubMed
-
J KOREAN NEUROSURG SOC 2021 10.3340/jkns.2020.0135
Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer with Brain Metastasis : The Role of Gamma Knife Radiosurgery
Lee1, MH; Cho, KR; Choi, JW; Kong, DS; Seol, HJ; Nam, DH; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Lee, JI
View PubMed
-
J THORAC ONCOL 2021 10.1016/j.jtho.2020.12.009
A Response to the Letter to the Editor: Osimertinib Leads the Way Towards Improving Outcomes of EGFR-Mutant NSCLC With Leptomeningeal Metastases
Lee1, J; Ahn, MJ
View PubMed
-
FUTURE ONCOL 2021 10.2217/fon-2020-1087
Global longitudinal assessment of treatment outcomes in recurrent/metastatic nasopharyngeal carcinoma: GLANCE-NPC study
Ahn1, MJ; Chirovsky, D; Kuyas, H; Auclair, V; Abounit, S; Joo, S; Shah, R; Yang, MH
View PubMed
-
EUR J IMMUNOL 2021 10.1002/eji.202048966
Tumor infiltrated immune cell types support distinct immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer
Ku1, BM; Kim, Y; Lee, KY; Kim, SY; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
View PubMed
-
J NATL CANCER I 2021 10.1093/jnci/djaa063
Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040
Harrington1, KJ; Soulieres, D; Le Tourneau, C; Dinis, J; Licitra, LF; Ahn, MJ; Soria, A; Machiels, JPH; Mach, N; Mehra, R; Burtness, B; Ellison, MC; Cheng, JD; Chirovsky, DR; Swaby, RF; Cohen, EEW
View PubMed
-
ANN PALLIAT MED 2021 10.21037/apm-19-622
Dynamic contrast-enhanced MRI for response evaluation of non-small cell lung cancer in therapy with epidermal growth factor receptor tyrosine kinase inhibitors: a pilot study
Kim1, JH; Lee, JW; Park, K; Ahn, MJ; Moon, JW; Ham, SY; Yi, CA
View PubMed
-
TRANSL LUNG CANCER R 2021 10.21037/tlcr-20-1128
Comprehensive evaluation of the clinical utility of plasma EGFR test in non-small cell lung cancer patients with acquired resistance to first-line EGFR inhibitors
Kim1, H; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM
View PubMed
-
FUTURE ONCOL 2021 10.2217/fon-2020-1119
ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib
Kim1, ES; Barlesi, F; Mok, T; Ahn, MJ; Shen, JW; Zhang, PK; Ou, SHI
View PubMed
-
J CANCER RES CLIN 2021 10.1007/s00432-021-03527-4
Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05
Park1, JH; You, GL; Ahn, MJ; Kim, SW; Hong, MH; Han, JY; Ock, CY; Lee, JS; Oh, IJ; Lee, SY; Kim, CH; Min, YJ; Choi, YH; Ryu, JS; Park, SH; Ahn, HK; Shim, BY; Lee, KH; Lee, SY; Kim, JS; Yi, J; Choi, SK; An, H; Kang, JH
View PubMed
-
CURR OPIN ONCOL 2021 10.1097/CCO.0000000000000698
Immune checkpoint inhibitors in driver mutation-positive nonsmall cell lung cancer: is there a role?
Lee1, J; Ahn, MJ
View PubMed
-
IMMUNE NETW 2020 10.4110/in.2020.20.e48
Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 Abs
Kim1, KH; Hur, JY; Koh, J; Cho, J; Ku, BM; Koh, JY; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ; Shin, EC
View PubMed
-
EUR J CARDIO-THORAC 2020 10.1093/ejcts/ezaa181
Utility of positron emission-computed tomography for predicting pathological response in resectable oesophageal squamous cell carcinoma after neoadjuvant chemoradiation
Lee1, J; Choi, JY; Lim, SW; Ahn, MJ; Park, K; Zo, JI; Shim, YM; Oh, D; Sun, JM
View PubMed
-
ANN ONCOL 2020 10.1016/j.annonc.2020.08.2234
Osimertinib in central nervous system progressive EGFR-mutant lung cancer do we need to detect T790M?
Park1, S; Ahn, MJ
View PubMed
-
ANN ONCOL 2020 10.1016/j.annonc.2020.08.2100
Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor AURA3 overall survival analysis
Papadimitrakopoulou1, VA; Mok, TS; Han, JY; Ahn, MJ; Delmonte, A; Ramalingam, SS; Kim, SW; Shepherd, FA; Laskin, J; He, Y; Akamatsu, H; Theelen, WSME; Su, WC; John, T; Sebastian, M; Mann, H; Miranda, M; Laus, G; Rukazenkov, Y; Wu, YL
View PubMed
-
J THORAC ONCOL 2020 10.1016/j.jtho.2020.06.018
Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status
Lee1, J; Choi, YL; Han, J; Park, S; Jung, HA; Su, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
View PubMed
-
SCI REP-UK 2020 10.1038/s41598-020-77036-8
An increase of CD8(+)T cell infiltration following recurrence is a good prognosticator in HNSCC
So1, YK; Byeon, SJ; Ku, BM; Ko, YH; Ahn, MJ; Son, YI; Chung, MK
View PubMed
-
J CLIN ONCOL 2020 10.1200/JCO.20.00505
Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer Second Interim Analysis of the Phase III ALTA-1L Trial
Camidge1, DR; Kim, HR; Ahn, MJ; Yang, JCH; Han, JY; Hochmair, MJ; Lee, KH; Delmonte, A; Garcia Campelo, MR; Kim, DW; Griesinger, F; Felip, E; Califano, R; Spira, A; Gettinger, SN; Tiseo, M; Lin, HM; Gupta, N; Hanley, MJ; Ni, QH; Zhang, PK; Popat, S
View PubMed
-
SCI REP-UK 2020 10.1038/s41598-020-76130-1
Regulatory -(FoxP3(+)) T cells and TGF-beta predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer
Koh1, J; Hur, JY; Lee, KY; Kim, MS; Heo, JY; Ku, BM; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
View PubMed
-
CANCER RES TREAT 2020 10.4143/crt.2020.278
EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
Park1, S; Ku, BM; Jung, HA; Sun, JM; Ahn, JS; Lee, SH; Park, K; Ahn, MJ
View PubMed
-
CANCER RES TREAT 2020 10.4143/crt.2020.245
Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea
Lim1, SM; Kim, SW; Cho, BC; Kang, JH; Ahn, MJ; Kim, DW; Kim, YC; Lee, JS; Lee, JS; Lee, SY; Park, KU; An, HJ; Cho, EK; Jang, TW; Kim, BS; Kim, JH; Lee, SS; Na, II; Yoo, SS; Lee, KH
View PubMed
-
BIOLOGY-BASEL 2020 10.3390/biology9100326
Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations Are They Different from Those with Common EGFR Mutations?
Jung1, HA; Park, S; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Park, K
View PubMed
-
J IMMUNOTHER CANCER 2020 10.1136/jitc-2020-001199
Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity
Hong1, TH; Cha, H; Shim, JH; Lee, B; Chung, J; Lee, C; Kim, NKD; Choi, YL; Hwang, S; Lee, Y; Park, S; Jung, HA; Kim, JY; Park, YH; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH; Park, WY
View PubMed
-
ANN ONCOL 2020 10.1016/j.annonc.2020.06.017
A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy
Park1, S; Lee, MH; Seong, M; Kim, ST; Kang, JH; Cho, BC; Lee, KH; Cho, EK; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
View PubMed
-
TRANSL LUNG CANCER R 2020 10.21037/tlcr-20-379
The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer
Jung1, HA; Woo, SY; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM
View PubMed
-
J NEURO-ONCOL 2020 10.1007/s11060-020-03617-2
Diagnostic accuracy of MR imaging of patients with leptomeningeal seeding from lung adenocarcinoma based on 2017 RANO proposal added value of contrast-enhanced 2D axial T2 FLAIR
Seong1, M; Park, S; Kim, ST; Park, SG; Kim, YK; Kim, HJ; Ahn, MJ
View PubMed
-
J THORAC ONCOL 2020 10.1016/j.jtho.2020.06.006
Molecular Testing in Lung Cancer Still Big Gap in Implementation for Real-World Use
Ahn1, MJ
View PubMed
-
CANCER 2020 10.1002/cncr.33048
Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum-based chemotherapy
Park1, S; Shim, J; Mortimer, PGS; Smith, SA; Godin, RE; Hollingsworth, SJ; Kim, HJ; Jung, HA; Sun, JM; Park, WY; Ahn, JS; Ahn, MJ; Lee, SH; Park, K
View PubMed
-
BRIT J CANCER 2020 10.1038/s41416-020-01074-2
Mouse-human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck
Kim1, HR; Kang, HN; Yun, MR; Ju, KY; Choi, JW; Jung, DM; Pyo, KH; Hong, MH; Ahn, MJ; Sun, JM; Kim, HS; Kim, J; Yoo, J; Kim, KR; Koh, YW; Kim, SH; Choi, EC; Yoon, SO; Shim, HS; Paik, S; Kim, TM; Cho, BC
View PubMed
-
EXPERT OPIN INV DRUG 2020 10.1080/13543784.2020.1804855
Phase I clinical trial of KML001 monotherapy in patients with advanced solid tumors
Kim1, S; Kim, S; Park, YS; Park, JO; Lim, HY; Ahn, JS; Lee, J; Sun, JM; Kang, WK; Han, R; Kim, J; Ahn, MJ
View PubMed
-
LUNG CANCER 2020 10.1016/j.lungcan.2020.05.033
Ten-year patient journey of stage III non-small cell lung cancer patients A single-center, observational, retrospective study in Korea (Realtime autOmatically updated data warehOuse in healTh care; UNIVERSE-ROOT study)
Jung1, HA; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Park, K
View PubMed
-
LUNG CANCER 2020 10.1016/j.lungcan.2020.05.035
Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer
Jung1, HA; Noh, JM; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Pyo, H; Ahn, YC; Park, K
View PubMed
-
BMC CANCER 2020 10.1186/s12885-020-07214-4
Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer real-world data in Korea
Kim1, H; Kwon, M; Kim, B; Jung, HA; Sun, JM; Lee, SH; Park, K; Ahn, MJ
View PubMed
-
SCI REP-UK 2020 10.1038/s41598-020-70168-x
Metabolic radiogenomics in lung cancer associations between FDG PET image features and oncogenic signaling pathway alterations
Kim1, G; Kim, J; Cha, H; Park, WY; Ahn, JS; Ahn, MJ; Park, K; Park, YJ; Choi, JY; Lee, KH; Lee, SH; Moon, SH
View PubMed
-
J THORAC ONCOL 2020 10.1016/j.jtho.2020.05.001
Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic
Dingemans1, AMC; Soo, RA; Jazieh, AR; Rice, SJ; Kim, YT; Teo, LLS; Warren, GW; Xiao, SY; Smit, EF; Aerts, JG; Yoon, SH; Veronesi, G; De Cobelli, F; Ramalingam, SS; Garassino, MC; Wynes, MW; Behera, M; Haanen, J; Lu, S; Peters, S; Ahn, MJ; Scagliotti, GV; Adjei, AA; Belani, CP
View PubMed
-
J THORAC DIS 2020 10.21037/jtd.2019.08.29
Are there any ethnic differences in the efficacy and safety of immune checkpoint inhibitors for treatment of lung cancer?
Lee1, J; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
View PubMed
-
ANN ONCOL 2020 10.1016/j.annonc.2020.04.004
HLA-corrected tumor mutation burden and homologous recombination de fi ciency for the prediction of response to PD -(L)1 blockade in advanced non -small -cell lung cancer patients
Shim1, JH; Kim, HS; Cha, H; Kim, S; Kim, TM; Anagnostou, V; Choi, YL; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Park, WY; Lee, SH
View PubMed
-
EXPERT OPIN PHARMACO 2020 10.1080/14656566.2020.1798932
Evaluating entrectinib as a treatment option for non-small cell lung cancer
Lee1, JY; Park, S; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
View PubMed
-
J CANCER RES CLIN 2020 10.1007/s00432-020-03316-5
Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors Korean cancer study group HN 18-12
Park1, J; Chun, SH; Lee, YG; Chang, H; Lee, KW; Kim, HR; Shin, SH; An, HJ; Lee, KE; Hwang, IG; Ahn, MJ; Kim, SB; Keam, B
View PubMed
-
EUR J CANCER 2020 10.1016/j.ejca.2020.03.029
Outstanding clinical efficacy of PD-1/PD-L1 inhibitors for pulmonary pleomorphic carcinoma
Lee1, J; La Choi, Y; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM
View PubMed
-
CANCER 2020 10.1002/cncr.32809
Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer
Lee1, J; Kim, HS; Lee, B; Kim, HK; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH
View PubMed
-
JAMA Oncol 2020 10.1001/jamaoncol.2020.0237
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer The MYSTIC Phase 3 Randomized Clinical Trial
Rizvi1, NA; Cho, BC; Reinmuth, N; Lee, KH; Luft, A; Ahn, MJ; van den Heuvel, MM; Cobo, M; Vicente, D; Smolin, A; Moiseyenko, V; Antonia, SJ; Le Moulec, S; Robinet, G; Natale, R; Schneider, J; Shepherd, FA; Geater, SL; Garon, EB; Kim, ES; Goldberg, SB; Nakagawa, K; Raja, R; Higgs, BW; Boothman, AM; Zhao, L; Scheuring, U; Stockman, PK; Chand, VK; Peters, S
View PubMed
-
IN VIVO 2020 10.21873/invivo.11920
Characteristics and Clinical Outcomes of Non-small Cell Lung Cancer Patients in Korea With MET Exon 14 Skipping
Hur1, JY; Ku, BM; Shim, JH; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
View PubMed
-
NAT COMMUN 2020 10.1038/s41467-020-16164-1
Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma
Kim1, N; Kim, HK; Lee, K; Hong, Y; Cho, JH; Choi, JW; Lee, J; Suh, YL; Ku, BM; Eum, HH; Choi, S; Choi, YL; Joung, JG; Park, WY; Jung, HA; Sun, JM; Lee, SN; Ahn, JS; Park, K; Ahn, MJ; Lee, HO
View PubMed
-
Journal of thoracic disease 2020 10.21037/jtd.2020.03.23
Adjuvant therapy in stage IIIA-N2 non-small cell lung cancer after neoadjuvant concurrent chemoradiotherapy followed by surgery
Shin1, S; Kim, HK; Cho, JH; Choi, YS; Kim, K; Kim, J; Zo, JI; Sun, JM; Ahn, MJ; Park, K; Pyo, H; Ahn, YC; Shim, YM
View PubMed
-
CLIN LUNG CANCER 2020 10.1016/j.cllc.2019.11.006
Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests
Byeon1, S; Lee, B; Park, WY; Choi, YL; Jung, HA; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH
View PubMed
-
J THEOR BIOL 2020 10.1016/j.jtho.2019.11.004
Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial
Huber1, RM; Hansen, KH; Rodriguez, LPA; West, HL; Reckamp, KL; Leighl, NB; Tiseo, M; Smit, EF; Kim, DW; Gettinger, SN; Hochmair, MJ; Kim, SW; Langer, CJ; Ahn, MJ; Kim, ES; Kerstein, D; Groen, HJM; Camidge, DR
View PubMed
-
INVEST NEW DRUG 2020 10.1007/s10637-019-00795-3
Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer
Ku1, BM; Bae, YH; Lee, KY; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
View PubMed
-
ANN ONCOL 2020 10.1016/j.annonc.2020.01.013
TATTON: a multi-arm, phase lb trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
Oxnard1, GR; Yang, JCH; Yu, H; Kim, SW; Saka, H; Horn, L; Goto, K; Ohe, Y; Mann, H; Thress, KS; Frigault, MM; Vishwanathan, K; Ghiorghiu, D; Ramalingam, SS; Ahn, MJ
View PubMed
-
J THORAC ONCOL 2020 10.1016/j.jtho.2019.12.113
Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis
Ahn1, MJ; Chiu, CH; Cheng, Y; Han, JY; Goldberg, SB; Greystoke, A; Crawford, J; Zhao, YQ; Huang, XN; Johnson, M; Vishwanathan, K; Yates, JWT; Brown, AP; Mendoza-Naranjo, A; Mok, T
View PubMed
-
CELL MOL IMMUNOL 2020 10.1038/s41423-020-0427-6
PD-1 blockade-unresponsive human tumor-infiltrating CD8(+) T cells are marked by loss of CD28 expression and rescued by IL-151
Kim1, KH; Kim, HK; Kim, HD; Kim, CG; Lee, H; Han, JW; Choi, SJ; Jeong, S; Jeon, M; Kim, H; Koh, J; Ku, BM; Park, SH; Ahn, MJ; Shin, EC
View PubMed
-
J THORAC ONCOL 2020 10.1016/j.jtho.2019.11.004
Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial
Huber1, RM; Hansen, KH; Rodriguez, LPA; West, HL; Reckamp, KL; Leighl, NB; Tiseo, M; Smit, EF; Kim, DW; Gettinger, SN; Hochmair, MJ; Kim, SW; Langer, CJ; Ahn, MJ; Kim, ES; Kerstein, D; Groen, HJM; Camidge, DR
View PubMed
-
J MOL DIAGN 2020 10.1016/j.jmoldx.2019.10.015
Junction Location Identifier (JuLI) Accurate Detection of DNA Fusions in Clinical Sequencing for Precision Oncology
Shin1, HT; Kim, NKD; Yun, JW; Lee, B; Kyung, S; Lee, KW; Ryu, D; Kim, J; Bae, JS; Park, D; Choi, YL; Lee, SH; Ahn, MJ; Park, K; Park, WY
View PubMed
-
ORAL ONCOL 2020 10.1016/j.oraloncology.2019.104526
Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study
Grunwald1, V; Chirovsky, D; Cheung, WY; Bertolini, F; Ahn, MJ; Yang, MH; Castro, G; Berrocal, A; Sjoquist, K; Kuyas, H; Auclair, V; Guillaume, X; Joo, S; Shah, R; Harrington, K
View PubMed
-
LANCET ONCOL 2020 10.1016/S1470-2045(19)30785-5
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
Sequist1, LV; Han, JY; Ahn, MJ; Cho, BC; Yu, H; Kim, SW; Yang, JCH; Lee, JS; Su, WC; Kowalski, D; Orlov, S; Cantarini, M; Verheijen, RB; Mellemgaard, A; Ottesen, L; Frewer, P; Ou, XL; Oxnard, G
View PubMed
-
J THORAC ONCOL 2020 10.1016/j.jtho.2019.10.022
Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC
Tan1, WL; Chua, KLM; Lin, CC; Lee, VHF; Tho, LM; Chan, AW; Ho, GF; Reungwetwattana, T; Yang, JC; Kim, DW; Soo, RA; Ahn, YC; Onishi, H; Ahn, MJ; Mok, TSK; Tan, DSW; Yang, F
View PubMed
-
LANCET ONCOL 2020 10.1016/S1470-2045(19)30690-4
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials
Drilon1, A; Siena, S; Dziadziuszko, R; Barlesi, F; Krebs, MG; Shaw, AT; de Braud, F; Rolfo, C; Ahn, MJ; Wolf, J; Seto, T; Cho, BC; Patel, MR; Chiu, CH; John, T; Goto, K; Karapetis, CS; Arkenau, HT; Kim, SW; Ohe, Y; Li, YC; Chae, YK; Chung, CH; Otterson, GA; Murakami, H; Lin, CC; Tan, DSW; Prenen, H; Riehl, T; Chow-Maneval, E; Simmons, B; Cui, N; Johnson, A; Eng, S; Wilson, TR; Doebele, RC
View PubMed
-
Cancer Med 2020 10.1002/cam4.2868
PD-1 inhibitors for non-small cell lung cancer patients with special issues: Real-world evidence
Byeon1, S; Cho, JH; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
View PubMed
-
J CLIN ONCOL 2020 10.1200/JCO.19.00457
Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation?Positive Non?Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study
Yang1, JCH; Kim, SW; Kim, DW; Lee, JS; Cho, BC; Ahn, JS; Lee, DH; Kim, TM; Goldman, JW; Natale, RB; Brown, AP; Collins, B; Chmielecki, J; Vishwanathan, K; Mendoza-Naranjo, A; Ahn, MJ
View PubMed
-
J CLIN ONCOL 2020 10.1200/JCO.19.00931
Osimertinib for Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)
Cho1, JH; Lim, SH; An, HJ; Kim, KH; Park, KU; Kang, EJ; Choi, YH; Ahn, MS; Lee, MH; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
View PubMed
-
PLoS One 2020 10.1371/journal.pone.0229299
Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma
Lim1, JH; Choi, JY; Im, Y; Yoo, H; Jhun, BW; Jeong, BH; Park, HY; Lee, K; Kim, H; Kwon, OJ; Han, J; Ahn, MJ; Kim, J; Um, SW
View PubMed
-
BMC OPHTHALMOL 2020 10.1186/s12886-019-1285-9
Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors
Shin1, E; Lim, DH; Han, JS; Nam, D; Park, K; Ahn, MJ; Kang, WK; Lee, JY; Ahn, JS; Lee, SH; Sun, JM; Jung, HA; Chung, TY
View PubMed
-
RESP RES 2020 10.1186/s12931-019-1254-0
Impact of diffusing lung capacity before and after neoadjuvant concurrent chemoradiation on postoperative pulmonary complications among patients with stage IIIA/N2 non-small-cell lung cancer
Shin1, S; Choi, YS; Jung, JJ; Im, Y; Shin, SH; Kang, D; Cho, JH; Kim, HK; Kim, J; Zo, JI; Shim, YM; Park, K; Ahn, MJ; Ahn, YC; Lee, G; Cho, J; Lee, HY; Park, HY
View PubMed
-
J Stroke 2020 10.5853/jos.2019.02278
Cancer Related Stroke: An Emerging Subtype of Ischemic Stroke with Unique Pathomechanisms
Bang1, OY; Chung, JW; Lee, MJ; Seo, WK; Kim, GM; Ahn, MJ
View PubMed
-
Oncoimmunology 2020 10.1080/2162402X.2020.1722023
Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment
Kim1, KH; Hur, JY; Cho, J; Ku, BM; Koh, J; Koh, JY; Sun, JM; Lee, SN; Ahn, JS; Park, K; Ahn, MJ; Shin, EC
View PubMed
-
CANCER RES TREAT 2020 10.4143/crt.2019.186
Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea
Lee1, K; Jung, HA; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahm, MJ
View PubMed
-
CANCER RES TREAT 2020 10.4143/crt.2019.200
Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies
Ahn1, MJ; Han, JY; Kim, DW; Cho, BC; Kang, JH; Kim, SW; Yang, JCH; Mitsudomi, T; Lee, JS
View PubMed
-
HEAD NECK-J SCI SPEC 2020 10.1002/hed.26067
Prevalence of NUT carcinoma in head and neck: Analysis of 362 cases with literature review
Lee1, T; Cho, J; Baek, CH; Son, YI; Jeong, HS; Chung, MK; Hong, SD; Ahn, YC; Oh, DR; Noh, JM; Park, K; Ahn, MJ; Kim, HJ; Kim, YK; Ko, YH
View PubMed
-
LANCET ONCOL 2019 10.1016/S1470-2045(19)30504-2
Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study
Ahn1, MJ; Han, JY; Lee, KH; Kim, SW; Kim, DW; Lee, YG; Cho, EK; Kim, JH; Lee, GW; Lee, JS; Min, YJ; Kim, JS; Lee, SS; Kim, HR; Hong, MH; Ahn, JS; Sun, JM; Kim, HT; Lee, DH; Kim, S; Cho, BC
View PubMed
-
LANCET ONCOL 2019 10.1016/S1470-2045(19)30626-6
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
Kato1, K; Cho, BC; Takahashi, M; Okada, M; Lin, CY; Chin, K; Kadowaki, S; Ahn, MJ; Hamamoto, Y; Doki, Y; Yen, CC; Kubota, Y; Kim, SB; Hsu, CH; Holtved, E; Xynos, I; Kodani, M; Kitagawa, Y
View PubMed
-
CANCER 2019 10.1002/cncr.32503
Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer
Papadimitrakopoulou1, VA; Han, JY; Ahn, MJ; Ramalingam, SS; Delmonte, A; Hsia, TC; Laskin, J; Kim, SW; He, Y; Tsai, CM; Hida, T; Maemondo, M; Kato, T; Jenkins, S; Patel, S; Huang, XN; Laus, G; Markovets, A; Thress, KS; Wu, YL; Mok, T
View PubMed
-
J THORAC ONCOL 2019 10.1016/j.jtho.2019.06.010
Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC
Antonia1, SJ; Balmanoukian, A; Brahmer, J; Ou, SHI; Hellmann, MD; Kim, SW; Ahn, MJ; Kim, DW; Gutierrez, M; Liu, SV; Schoffski, P; Jager, D; Jamal, R; Jerusalem, G; Lutzky, J; Nemunaitis, J; Calabro, L; Weiss, J; Gadgeel, S; Bhosle, J; Ascierto, PA; Rebelatto, MC; Narwal, R; Liang, MN; Xiao, F; Antal, J; Abdullah, S; Angra, N; Gupta, AK; Khleif, SN; Segal, NH
View PubMed
-
J CLIN ONCOL 2019 10.1200/JCO.19.00934
Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study
Garon1, EB; Hellmann, MD; Rizvi, NA; Carcereny, E; Leighl, NB; Ahn, MJ; Eder, JP; Balmanoukian, AS; Aggarwal, C; Horn, L; Patnaik, A; Gubens, M; Ramalingam, SS; Felip, E; Goldman, JW; Scalzo, C; Jensen, E; Kush, DA; Hui, R
View PubMed
-
STROKE 2019 10.1161/STROKEAHA.119.026373
Circulating DNAs, a Marker of Neutrophil Extracellular Traposis and Cancer-Related Stroke: The OASIS-Cancer Study
Bang1, OY; Chung, JW; Cho, YH; Oh, MJ; Seo, WK; Kim, GM; Ahn, MJ
View PubMed
-
EUR J CANCER 2019 10.1016/j.ejca.2019.08.001
Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing
Kim1, HS; Cha, H; Kim, JH; Park, WY; Choi, YL; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH
View PubMed
-
KOREAN JOURNAL OF INTERNAL MEDICINE 2019 10.3904/kjim.2017.234
Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
Kim1, MJ; Kim, SM; Jung, HA; Hong, JY; Chang, WJ; Choi, MK; Kim, HS; Sun, JM; Park, K; Ahn, MJ
View PubMed
-
NAT COMMUN 2019 10.1038/s41467-019-12159-9
DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load
Jung1, H; Kim, HS; Kim, JY; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Esteller, M; Lee, SH; Choi, JK
View PubMed
-
J THORAC ONCOL 2019 10.1016/j.jtho.2019.05.014
DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC
Park1, S; Lee, H; Lee, B; Lee, SH; Sun, JM; Park, WY; Ahn, JS; Ahn, MJ; Park, K
View PubMed
-
J THORAC ONCOL 2019 10.1016/j.jtho.2019.05.033
Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor
Kim1, Y; Kim, CH; Lee, HY; Lee, SH; Kim, HS; Lee, S; Cha, H; Hong, S; Kim, K; Seo, SW; Sun, JM; Ahn, MJ; Ahn, JS; Park, K
View PubMed
-
LUNG CANCER 2019 10.1016/j.lungcan.2019.05.024
Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma
Park1, S; Shim, JH; Lee, B; Cho, I; Park, WY; Kim, Y; Lee, SH; Choi, YL; Han, J; Ahn, JS; Ahn, MJ; Park, K; Sun, JM
View PubMed
-
J CLIN ONCOL 2019 10.1200/JCO.2017.77.3184
Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial
Cho1, J; Kim, HS; Ku, BM; Choi, YL; Cristescu, R; Han, J; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
View PubMed
-
SCI REP-UK 2019 10.1038/s41598-019-48674-4
Predictive and Prognostic Value of F-18-fluorodeoxyglucose Uptake Combined with Thymidylate Synthase Expression in Patients with Advanced Non-Small Cell Lung Cancer
Moon1, SH; Sun, JM; Ahn, JS; Park, K; Kim, BT; Lee, KH; Ahn, MJ; Choi, JY
View PubMed
-
J THORAC ONCOL 2019 10.1016/j.jtho.2019.03.022
Advanced-Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018
Remon1, J; Ahn, MJ; Girard, N; Johnson, M; Kim, DW; Lopes, G; Pillai, RN; Solomon, B; Villacampa, G; Zhou, Q
View PubMed
-
PATHOL RES PRACT 2019 10.1016/j.prp.2019.152441
Histopathologic characteristics of advanced-stage ROS1-rearranged non-small-cell lung cancers
Park1, E; Choi, YL; Ahn, MJ; Han, J
View PubMed
-
CLIN CANCER RES 2019 10.1158/1078-0432.CCR-18-2740
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
Jung1, KH; LoRusso, P; Burris, H; Gordon, M; Bang, YJ; Hellmann, MD; Cervantes, A; de Olza, MO; Marabelle, A; Hodi, S; Ahn, MJ; Emens, LA; Barlesi, F; Hamid, O; Calvo, E; McDermott, D; Soliman, H; Rhee, I; Lin, R; Pourmohamad, T; Suchomel, J; Tsuhako, A; Morrissey, K; Mahrus, S; Morley, R; Pirzkall, A; Davis, SL
View PubMed
-
SCI REP-UK 2019 10.1038/s41598-019-45117-y
Prognostic Impact of Longitudinal Monitoring of Radiomic Features in Patients with Advanced Non-Small Cell Lung Cancer
Bak1, SH; Park, H; Sohn, I; Lee, SH; Ahn, MJ; Lee, HY
View PubMed
-
CLIN LUNG CANCER 2019 10.1016/j.cllc.2018.12.021
Transthoracic Rebiopsy for Mutation Analysis in Lung Adenocarcinoma: Outcomes and Risk Factors for the Acquisition of Nondiagnostic Specimens in 199 Patients
Da Nam1, B; Kim, TJ; Park, K; Ahn, MJ; Choi, YL; Chung, MJ; Kim, TS; Lee, KS
View PubMed
-
J CANCER RES CLIN 2019 10.1007/s00432-019-02889-0
Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma
Cho1, JH; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM
View PubMed
-
J THORAC ONCOL 2019 10.1016/j.jtho.2019.01.016
Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC
Barlesi1, F; Garon, EB; Kim, DW; Felip, E; Han, JY; Kim, JH; Ahn, MJ; Fidler, MJ; Gubens, MA; de Castro, G; Surmont, V; Li, Q; Deitz, AC; Lubiniecki, GM; Herbst, RS
View PubMed
-
J IMMUNOTHER CANCER 2019 10.1186/s40425-019-0609-x
Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma
Park1, S; Joung, JG; Min, YW; Nam, JY; Ryu, D; Oh, D; Park, WY; Lee, SH; Choi, YL; Ahn, JS; Ahn, MJ; Park, K; Sun, JM
View PubMed
-
CLIN LUNG CANCER 2019 10.1016/j.cllc.2018.12.020
Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor
Lee1, J; Sun, JM; Lee, SH; Ahn, JS; Park, K; Choi, YL; Ahn, MJ
View PubMed
-
J THORAC ONCOL 2019 10.1016/j.jtho.2019.03.005
Combination of Osimertinib with Durvalumab in Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer: Is There Room for Reinvestigation?
Ahn1, MJ
View PubMed
-
CANCER RES TREAT 2019 10.4143/crt.2018.125
EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy
Park1, SE; Noh, JM; Kim, YJ; Lee, HS; Cho, JH; Lim, SW; Ahn, YC; Pyo, H; Choi, YL; Han, J; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
View PubMed
-
Lancet Respir Med 2019 10.1016/S2213-2600(18)30500-9
Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study
Leigh1, NB; Hellmann, MD; Hui, RN; Carcereny, E; Felip, E; Ahn, MJ; Eder, JP; Balmanoukian, AS; Aggarwal, C; Horn, L; Patnaik, A; Gubens, M; Ramalingam, SS; Lubiniecki, GM; Zhang, J; Piperdi, B; Garon, EB
View PubMed
-
RADIOTHER ONCOL 2019 10.1016/j.radonc.2019.01.005
Dosimetric predictors for postoperative pulmonary complications in esophageal cancer following neoadjuvant chemoradiotherapy and surgery
Cho1, WK; Oh, D; Kim, HK; Ahn, YC; Noh, JM; Shim, YM; Zo, JI; Choi, YS; Sun, JM; Lee, SH; Ahn, MJ; Park, K; Nam, H
View PubMed
-
CLIN CANCER RES 2019 10.1158/1078-0432.CCR-18-1449
The First-week Proliferative Response of Peripheral Blood PD-1(+)CD8(+) T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors
Kim1, KH; Cho, J; Ku, BM; Koh, J; Sun, JM; Lee, SH; Ahn, JS; Cheon, J; Min, YJ; Park, SH; Park, K; Ahn, MJ; Shin, EC
View PubMed
-
CANCER RES TREAT 2019 10.4143/crt.2018.117
Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
Kim1, Y; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM
View PubMed
-
LUNG CANCER 2019 10.1016/j.lungcan.2019.01.012
Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer
Lee1, K; Kim, Y; Jung, HA; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Choi, YL; Sun, JM
View PubMed
-
CANCER RES TREAT 2019 10.4143/crt.2018.151
Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea
Byeon1, S; Kim, Y; Lim, SW; Cho, JH; Park, S; Lee, J; Sun, JM; Choi, YL; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
View PubMed
-
CANCER RES TREAT 2019 10.4143/crt.2018.324
A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13
Yoo1, KH; Lee, SJ; Cho, J; Lee, KH; Park, KU; Kim, KH; Cho, EK; Choi, YH; Kim, HR; Kim, HG; Ahn, HJ; Lee, HY; Yun, HJ; Kang, JH; Jeong, J; Choi, MY; Jung, SH; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
View PubMed
-
CANCER RES TREAT 2019 10.4143/crt.2018.366
Salvage Concurrent Chemo-radiation Therapy for Loco-regional Recurrence Following Curative Surgery of Non-small Cell Lung Cancer
Lee1, KH; Ahn, YC; Pyo, H; Noh, JM; Park, SG; Kim, TG; Lee, E; Nam, H; Lee, H; Sun, JM; Ahn, JS; Ahn, MJ; Park, K
View PubMed
-
CANCER DISCOV 2019 10.1158/2159-8290.CD-18-0839
A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105
Drilon1, A; Fu, SQ; Patel, MR; Fakih, M; Wang, D; Olszanski, AJ; Morgensztern, D; Liu, SV; Cho, BC; Bazhenova, L; Rodriguez, CP; Doebele, RC; Wozniak, A; Reckamp, KL; Seery, T; Nikolinakos, P; Hu, ZY; Oliver, JW; Trone, D; McArthur, K; Patel, R; Multani, PS; Ahn, MJ
View PubMed
-
LUNG CANCER 2019 10.1016/j.lungcan.2018.12.027
Incidence of brain metastasis in lung adenocarcinoma at initial diagnosis on the basis of stage and genetic alterations
Yang1, B; Lee, H; Um, SW; Kim, K; Zo, JI; Shim, YM; Kwon, OJ; Lee, KS; Ahn, MJ; Kim, H
View PubMed
-
CANCER 2019 10.1002/cncr.31891
Osimertinib in Patients With T790M Mutation-Positive, Advanced Non-Small Cell Lung Cancer: Long-Term Follow-Up From a Pooled Analysis of 2 Phase 2 Studies
Ahn1, MJ; Tsai, CM; Shepherd, FA; Bazhenova, L; Sequist, LV; Hida, T; Yang, JCH; Ramalingam, SS; Mitsudomi, T; Janne, PA; Mann, H; Cantarini, M; Goss, G
View PubMed
-
CLIN NUCL MED 2019 10.1097/RLU.0000000000002394
Pretreatment Tumor 18F-FDG Uptake Improves Risk Stratification Beyond RECIST 1.1 in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer FDG Uptake and Risk Stratification
Moon1, SH; Sun, JM; Ahn, JS; Park, K; Ahn, MJ; Choi, JY
View PubMed
-
EUR J NUCL MED MOL I 2019 10.1007/s00259-018-4138-5
Correlations between metabolic texture features, genetic heterogeneity, and mutation burden in patients with lung cancer
Moon1, SH; Kim, J; Joung, JG; Cha, H; Park, WY; Ahn, JS; Ahn, MJ; Park, K; Choi, JY; Lee, KH; Kim, BT; Lee, SH
View PubMed
-
J THORAC ONCOL 2019 10.1016/j.jtho.2018.10.150
Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC
Kim1, Y; Lee, B; Shim, JH; Lee, SH; Park, WY; Choi, YL; Sun, JM; Ahn, JS; Ahn, MJ; Park, K
View PubMed
-
ANN ONCOL 2019 10.1093/annonc/mdy545
Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial
Herbst1, RS; Baas, P; Perez-Gracia, JL; Felip, E; Kim, DW; Han, JY; Molina, JR; Kim, JH; Arvis, CD; Ahn, MJ; Majem, M; Fidler, MJ; Surmont, V; de Castro, G; Garrido, M; Shentu, Y; Emancipator, K; Samkari, A; Jensen, EH; Lubiniecki, GM; Garon, EB
View PubMed
-
KOREAN JOURNAL OF INTERNAL MEDICINE 2019 10.3904/kjim.2018.179
Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer
Lim1, SW; Ahn, MJ
View PubMed
-
CANCER RES TREAT 2019 10.4143/crt.2018.012
Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma
Lim1, SM; Cho, SH; Hwang, IG; Choi, JW; Chang, H; Ahn, MJ; Park, KU; Kim, JW; Ko, YH; Ahn, HK; Cho, BC; Nam, BH; Chun, SH; Hong, JH; Kwon, JH; Choi, JG; Kang, EJ; Yun, T; Lee, KW; Kim, JH; Kim, JS; Lee, HW; Kim, MK; Jung, D; Kim, JE; Keam, B; Yun, HJ; Kim, S; Kim, HR
View PubMed
-
CANCER RES TREAT 2019 10.4143/crt.2018.138
Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-Mutated Non-small Cell Lung Cancer
Lee1, J; Shim, JH; Park, WY; Kim, HK; Sun, JM; Lee, SN; Ahn, JS; Park, K; Ahn, MJ
View PubMed
-
LANCET 2019 10.1016/S0140-6736(18)31999-8
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
Cohen1, EEW; Soulieres, D; Le Tourneau, C; Dinis, J; Licitra, L; Ahn, MJ; Soria, A; Machiels, JP; Mach, N; Mehra, R; Burtness, B; Zhang, PY; Cheng, J; Swaby, RF; Harrington, KJ
View PubMed
-
RADIAT ONCOL 2018 10.1186/s13014-018-1196-6
Clinical outcomes of radiation therapy for clinical T4b oesophageal cancer with airway invasion
Kim1, H; Oh, D; Ahn, YC; Park, K; Ahn, MJ; Lee, SH; Sun, JM; Shim, YM; Zo, JI; Choi, YS; Kim, HK; Cho, JH
View PubMed
-
NEW ENGL J MED 2018 10.1056/NEJMoa1810171
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer
Camidge1, DR; Kim, HR; Ahn, MJ; Yang, JCH; Han, JY; Lee, JS; Hochmair, MJ; Li, JYC; Chang, GC; Lee, KH; Gridelli, C; Delmonte, A; Campelo, RG; Kim, DW; Bearz, A; Griesinger, F; Morabito, A; Felip, E; Califano, R; Ghosh, S; Spira, A; Gettinger, SN; Tiseo, M; Gupta, N; Haney, J; Kerstein, D; Popat, S
View PubMed
-
J CLIN ONCOL 2018 10.1200/JCO.2018.77.7326
Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer
Wu1, YL; Zhang, L; Kim, DW; Liu, XQ; Lee, DH; Yang, JCH; Ahn, MJ; Vansteenkiste, JF; Su, WC; Felip, E; Chia, V; Glaser, S; Pultar, P; Zhao, S; Peng, B; Akimov, M; Tan, DSW
View PubMed
-
CANCER DISCOV 2018 10.1158/2159-8290.CD-18-0484
Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibit ROS1/TRK/ALK Solvent-Front Mutations
Drilon1, A; Ou, SHI; Cho, BC; Kim, DW; Lees, J; Lin, JJ; Zhu, VW; Ahns, MJ; Camidge, DR; Nguyen, J; Zhai, DY; Deng, W; Huang, ZD; Rogers, E; Liu, J; Whitten, J; Lim, JK; Stopatschinskaja, S; Hyman, DM; Doebele, RC; Cui, JJ; Shaw, AT
View PubMed
-
LUNG CANCER 2018 10.1016/j.lungcan.2018.08.003
Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial
Lim1, SW; Park, S; Kim, Y; Cho, JH; Park, SE; Lee, H; Kim, HK; Kim, SM; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
View PubMed
-
J CLIN ONCOL 2018 10.1200/JCO.2018.77.9363
CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)
Wu1, YL; Ahn, MJ; Garassino, MC; Han, JY; Katakami, N; Kim, HR; Hodge, R; Kaur, P; Brown, AP; Ghiorghiu, D; Papadimitrakopoulou, VA; Mok, TSK
View PubMed
-
J CLIN ONCOL 2018 10.1200/JCO.2017.77.5841
Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials
Camidge1, DR; Kim, DW; Tiseo, M; Langer, CJ; Ahn, MJ; Shaw, AT; Huber, RM; Hochmair, MJ; Lee, DH; Bazhenova, LA; Gold, KA; Ou, SHI; West, HL; Reichmann, W; Haney, J; Clackson, T; Kerstein, D; Gettinger, SN
View PubMed
-
J THORAC ONCOL 2018 10.1016/j.jtho.2018.05.026
Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice
Park1, S; Ahn, BC; Lim, SW; Sun, JM; Kim, HR; Hong, MH; Lee, SH; Ahn, JS; Park, K; La Choi, Y; Cho, BC; Ahn, MJ
View PubMed
-
J THORAC ONCOL 2018 10.1016/j.jtho.2018.04.038
Transient Asymptomatic Pulmonary Opacities During Osimertinib Treatment and its Clinical Implication
Lee1, H; Lee, HY; Sun, JM; Lee, SN; Kim, Y; Park, SE; Ahn, JS; Park, K; Ahn, MJ
View PubMed
-
Clin Pharmacol Drug Dev 2018 10.1002/cpdd.427
Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC
Tan1, EH; Lim, WT; Ahn, MJ; Ng, QS; Ahn, JS; Tan, DSW; Sun, JM; Han, M; Payumo, FC; Mckee, K; Yin, W; Credi, M; Agarwal, S; Jac, J; Park, K
View PubMed
-
SCI REP-UK 2018 10.1038/s41598-018-27273-9
Deciphering Clinicoradiologic Phenotype for Thymidylate Synthase Expression Status in Patients with Advanced Lung Adenocarcinoma Using a Radiomics Approach
Lee1, SW; Park, H; Lee, HY; Sohn, I; Lee, SH; Kang, J; Sun, JM; Ahn, MJ
View PubMed
-
CLIN COLORECTAL CANC 2018 10.1016/j.clcc.2018.01.005
Phase I Trial of Anti-MET Monoclonal Antibody in MET-Overexpressed Refractory Cancer
Lee1, J; Kim, ST; Park, S; Lee, S; Park, SH; Park, JO; Lim, HY; Ahn, H; Bok, H; Kim, KM; Ahn, MJ; Kang, WK; Park, YS
View PubMed
-
LUNG CANCER 2018 10.1016/j.lungcan.2018.02.020
Afatinib in heavily pretreated advanced NSCLC patients who progressed following prior gefitinib or erlotinib: Compassionate use program in Korea
Choi1, MK; Ahn, JS; Kim, YC; Cho, BC; Oh, IJ; Kim, SW; Lee, JS; Kim, JH; Ahn, MJ; Park, K
View PubMed
-
STROKE 2018 10.1161/STROKEAHA.118.020995
Association of Cancer Cell Type and Extracellular Vesicles With Coagulopathy in Patients With Lung Cancer and Stroke
Chung1, JW; Cho, YH; Ahn, MJ; Lee, MJ; Kim, GM; Chung, CS; Bang, OY
View PubMed
-
J CLIN ONCOL 2018 10.1200/JCO.2017.75.5587
Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer
Wu1, YL; Yang, JCH; Kim, DW; Lu, S; Zhou, JY; Seto, T; Yang, JJ; Yamamoto, N; Ahn, MJ; Takahashi, T; Yamanaka, T; Kemner, A; Roychowdhury, D; Paolini, J; Usari, T; Wilner, KD; Goto, K
View PubMed
-
Expert Opin Orphan Drugs 2018 10.1080/21678707.2018.1451325
Brigatinib for treatment of anaplastic lymphoma kinase-rearranged metastatic non-small cell lung cancer
Kim1, HK; Ahn, MJ
View PubMed
-
PLoS One 2018 10.1371/journal.pone.0194730
Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model
Ku1, BM; Choi, MK; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
View PubMed
-
ANN ONCOL 2018 10.1093/annonc/mdx820
CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials
Goss1, G; Tsai, CM; Shepherd, FA; Ahn, MJ; Bazhenova, L; Crino, L; de Marinis, F; Felip, E; Morabito, A; Hodge, R; Cantarini, M; Johnson, M; Mitsudomi, T; Janne, PA; Yang, JCH
View PubMed
-
J THORAC ONCOL 2018 10.1016/j.jtho.2017.10.007
Late-Onset Cholecystitis with Cholangitis after Avelumab Treatment in Non-Small Cell Lung Cancer
Cho1, JH; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
View PubMed
-
LUNG CANCER 2018 10.1016/j.lungcan.2018.01.004
Temporal and regional distribution of initial recurrence site in completely resected N1-stage II lung adenocarcinoma: The effect of postoperative adjuvant chemotherapy
Park1, BJ; Cho, JH; Lee, JH; Shin, S; Kim, HK; Choi, YS; Zo, JI; Shim, YM; Sun, JM; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Kim, J
View PubMed
-
J THORAC ONCOL 2018 10.1016/j.jtho.2017.10.014
KIF5B-MET Gene Rearrangement with Robust Antitumor Activity in Response to Crizotinib in Lung Adenocarcinoma
Cho1, JH; Ku, BM; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
View PubMed
-
BRIT J CANCER 2018 10.1038/bjc.2017.465
Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07)
Sun1, JM; Lee, KH; Kim, BS; Kim, HG; Min, YJ; Yi, SY; Yun, HJ; Jung, SH; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
View PubMed
-
Journal of thoracic disease 2018 10.21037/jtd.2018.03.55
Consolidation of immunotherapy becomes new standard of care in unresectable stage III non-small cell lung cancer
Ahn1, MJ
View PubMed
-
Oncoimmunology 2018 10.1080/2162402X.2017.1375642
Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer
Kim1, HI; Kim, M; Lee, SH; Park, SY; Kim, YN; Kim, H; Jeon, MJ; Kim, TY; Kim, SW; Kim, WB; Kim, SW; Lee, DH; Park, K; Ahn, MJ; Chung, JH; Shong, YK; Kim, WG; Kim, TH
View PubMed
-
J THORAC ONCOL 2018 10.1016/j.jtho.2017.10.003
Cell-free DNA Analysis in SCLC: Ready for Clinical Practice?
Ahn1, MJ
View PubMed
-
J THORAC ONCOL 2018 10.1016/j.jtho.2017.10.011
Increased Response Rates to Salvage Chemotherapy Administered after PD-1 /PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer
Park1, SE; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM
View PubMed
-
GENOME RES 2018 10.1101/gr.223263.117
SIDR: simultaneous isolation and parallel sequencing of genomic DNA and total RNA from single cells
Han1, KY; Kim, KT; Joung, JG; Son, DS; Kim, YJ; Jo, A; Jeon, HJ; Moon, HS; Yoo, CE; Chung, W; Eum, HH; Kim, S; Kim, HK; Lee, JE; Ahn, MJ; Lee, HO; Park, D; Park, WY
View PubMed
-
LUNG CANCER 2018 10.1016/j.lungcan.2017.11.020
Recurrence dynamics after trimodality therapy (Neoadjuvant concurrent chemoradiotherapy and surgery) in patients with stage IIIA (N2) lung cancer
Lee1, J; Kim, HK; Park, BJ; Cho, JH; Choi, YS; Zo, JI; Shim, YM; Pyo, H; Ahn, YC; Ahn, JS; Ahn, MJ; Park, K; Kim, J
View PubMed
-
J CLIN ONCOL 2017 10.1200/JCO.2017.73.9250
Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses
Mok1, TSK; Kim, SW; Wu, YL; Nakagawa, K; Yang, JJ; Ahn, MJ; Wang, J; Yang, JCH; Lu, Y; Atagi, S; Ponce, S; Shi, XJ; Rukazenkov, Y; Haddad, V; Thress, KS; Soria, JC
View PubMed
-
J THORAC ONCOL 2017 10.1016/j.jtho.2017.09.1954
Randomized Phase II Trial Comparing Chemoradiotherapy with Chemotherapy for Completely Resected Unsuspected N2-Positive Non-Small Cell Lung Cancer
Sun1, JM; Noh, JM; Oh, D; Kim, HK; Lee, SH; Choi, YS; Pyo, H; Ahn, JS; Jung, SH; Ahn, YC; Kim, J; Ahn, MJ; Zo, JI; Shim, YM; Park, K
View PubMed
-
INVEST NEW DRUG 2017 10.1007/s10637-017-0463-y
Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors
Lee1, SJ; Lee, SY; Lee, WS; Yoo, JS; Sun, JM; Lee, J; Park, SH; Park, JO; Ahn, MJ; Lim, HY; Kang, WK; Park, YS
View PubMed
-
Lancet Respir Med 2017 10.1016/S2213-2600(17)30378-8
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study
Ahn1, MJ; Kim, DW; Cho, BC; Kim, SW; Lee, JS; Ahn, JS; Kim, TM; Lin, CC; Kim, HR; John, T; Kao, S; Goldman, JW; Su, WC; Natale, R; Rabbie, S; Harrop, B; Overend, P; Yang, ZF; Yang, JCH
View PubMed
-
NAT COMMUN 2017 10.1038/s41467-017-01470-y
Prevalence and detection of low-allele-fraction variants in clinical cancer samples
Shin1, HT; Choi, YL; Yun, JW; Kim, NKD; Kim, SY; Jeon, HJ; Nam, JY; Lee, C; Ryu, D; Kim, SC; Park, K; Lee, E; Bae, JS; Son, DS; Joung, JG; Lee, J; Kim, ST; Ahn, MJ; Lee, SH; Ahn, JS; Lee, WY; Oh, BY; Park, YH; Lee, JE; Lee, KH; Kim, HC; Kim, KM; Im, YH; Park, K; Park, PJ; Park, WY
View PubMed
-
EXPERT REV MOL DIAGN 2017 10.1080/14737159.2017.1372196
An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer
Ku1, BM; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
View PubMed
-
CANCER RES TREAT 2017 10.4143/crt.2016.424
Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid Cancer
Lee1, MY; Ku, BM; Kim, HS; Lee, JY; Lim, SH; Sun, JM; Lee, SH; Park, K; Oh, YL; Hong, M; Jeong, HS; Son, YI; Baek, CH; Ahn, MJ
View PubMed
-
ASIA-PAC J CLIN ONCO 2017 10.1111/ajco.12645
Characteristics and outcomes of ALK plus non-small cell lung cancer patients in Korea
Lim1, SH; Yoh, KA; Lee, JS; Ahn, MJ; Kim, YJ; Kim, SH; Zhang, J; Patel, D; Swallow, E; Kageleiry, A; Galebach, P; Lee, D; Stein, K; Degun, R; Park, K
View PubMed
-
LUNG CANCER 2017 10.1016/j.lungcan.2017.08.017
Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers
Yu1, HA; Ahn, MJ; Cho, BC; Gerber, DE; Natale, RB; Socinski, MA; Giri, N; Quinn, S; Sbar, E; Zhang, H; Giaccone, G
View PubMed
-
CANCER RES TREAT 2017 10.4143/crt.2016.442
Role of Adjuvant Thoracic Radiation Therapy and Full Dose Chemotherapy in pN2 Non-small Cell Lung Cancer: Elucidation Based on Single Institute Experience
Park1, H; Oh, D; Ahn, YC; Pyo, H; Noh, JM; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Kim, HK; Choi, YS; Kim, J; Zo, JI; Shim, YM
View PubMed
-
SCI REP-UK 2017 10.1038/s41598-017-13456-3
Fluorescence-coded DNA Nanostructure Probe System to Enable Discrimination of Tumor Heterogeneity via a Screening of Dual Intracellular microRNA Signatures in situ
Shin1, SW; Lee, BS; Yang, K; Amornkitbamrung, L; Jang, MS; Ku, BM; Cho, SW; Lee, JH; Bae, H; Oh, BK; Ahn, MJ; Lim, YT; Um, SH
View PubMed
-
CANCER RES TREAT 2017 10.4143/crt.2016.423
Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study
Park1, K; Cho, EK; Bello, M; Ahn, MJ; Thongprasert, S; Song, EK; Soldatenkova, V; Depenbrock, H; Puri, T; Orlando, M
View PubMed
-
J CLIN ONCOL 2017 10.1200/JCO.2016.71.7629
Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer
Govindan1, R; Szczesna, A; Ahn, MJ; Schneider, CP; Mella, PFG; Barlesi, F; Han, BH; Ganea, DE; Von Pawel, J; Vladimirov, V; Fadeeva, N; Lee, KH; Kurata, T; Zhang, L; Tamura, T; Postmus, PE; Jassem, J; O'Byrne, K; Kopit, J; Li, MS; Tschaika, M; Reck, M
View PubMed
-
CANCER CHEMOTH PHARM 2017 10.1007/s00280-017-3396-4
Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors
Kim1, HK; Heo, MH; Lee, HS; Sun, JM; Lee, SH; Ahn, JS; Park, K; Ahn, MJ
View PubMed
-
ONCOTARGET 2017
Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer
Ku1, BM; Bae, YH; Koh, J; Sun, JM; Lee, SSH; Ahn, JS; Park, K; Ahn, MJ
View PubMed
-
CLIN LUNG CANCER 2017 10.1016/j.cllc.2017.01.005
Association Between Environmental Tobacco Smoke Exposure and the Occurrence of EGFR Mutations and ALK Rearrangements in Never-smokers With NoneSmall-cell Lung Cancer: Analyses From a Prospective Multinational ETS Registry
Soo1, RA; Kubo, A; Ando, M; Kawaguchi, T; Ahn, MJ; Ou, SHI
View PubMed
-
J CLIN ONCOL 2017 10.1200/JCO.2016.71.5904
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial
Kim1, DW; Tiseo, M; Ahn, MJ; Reckamp, KL; Hansen, KH; Kim, SW; Huber, RM; West, HL; Groen, HJM; Hochmair, MJ; Leighl, NB; Gettinger, SN; Langer, CJ; Rodriguez, LGPA; Smit, EF; Kim, ES; Reichmann, W; Haluska, FG; Kerstein, D; Camidge, DR
View PubMed
-
J THORAC ONCOL 2017 10.1016/j.jtho.2017.05.019
Scientific Advances in Thoracic Oncology 2016
Soo1, RA; Stone, ECA; Cummings, KM; Jett, JR; Field, JK; Groen, HJM; Mulshine, JL; Yatabe, Y; Bubendorf, L; Dacic, S; Rami-Porta, R; Detterbeck, FC; Lim, E; Asamura, H; Donington, J; Wakelee, HA; Wu, YL; Higgins, K; Senan, S; Solomon, B; Kim, DW; Johnson, M; Yang, JCH; Sequist, LV; Shaw, AT; Ahn, MJ; Costa, DB; Patel, JD; Horn, L; Gettinger, S; Peters, S; Wynes, MW; Faivre-Finn, C; Rudin, CM; Tsao, A; Baas, P; Kelly, RJ; Leighl, NB; Scagliotti, GV; Gandara, DR; Hirsch, FR; Spigel, DR
View PubMed
-
J CLIN ONCOL 2017 10.1200/JCO.2016.71.3701
Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement
Lim1, SM; Kim, HR; Lee, JS; Lee, KH; Lee, YG; JooMin, Y; Cho, EK; Lee, SS; Kim, BS; Choi, MY; Shim, HS; Chung, JH; La Choi, Y; Lee, MJ; Kim, M; Kim, JH; Ali, SM; Ahn, MJ; Cho, BC
View PubMed
-
WORLD J SURG 2017 10.1007/s00268-017-3908-8
Outcomes of Curative-Intent Surgery and Adjuvant Treatment for Pulmonary Large Cell Neuroendocrine Carcinoma
Kim1, KW; Kim, HK; Kim, J; Shim, YM; Ahn, MJ; Choi, YL
View PubMed
-
Theranostics 2017 10.7150/thno.19358
Blood Droplet-Based Cancer Diagnosis via Proteolytic Activity Measurement in Cancer Progression
Choi1, JW; Lee, H; Lee, G; Kim, YR; Ahn, MJ; Park, HJ; Eom, K; Kwon, T
View PubMed
-
CANCER RES TREAT 2017 10.4143/crt.2016.417
A Randomized Phase II Study of Leucovorin/5-Fluorouracil with or without Oxaliplatin (LV5FU2 vs. FOLFOX) for Curatively-Resected, Node-Positive Esophageal Squamous Cell Carcinoma
Lim1, SH; Shim, YM; Park, SH; Kim, HK; Choi, YS; Ahn, MJ; Park, K; Zo, JI; Sun, JM
View PubMed
-
Expert Opin Drug Saf. 2017 Apr;16(4):465-469. doi: 10.1080/14740338.2017.1300656. Epub 2017 Mar 8.
EGFR TKI combination with immunotherapy in non-small cell lung cancer
Ahn MJ11, Sun JM1, Lee SH1, Ahn JS1, Park K1.
View PubMed
-
J Clin Oncol. 2017 Apr 20;35(12):1288-1296. doi: 10.1200/JCO.2016.70.3223. Epub 2017 Feb 21.
Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component
Yang JC11, Ahn MJ1, Kim DW1, Ramalingam SS1, Sequist LV1, Su WC1, Kim SW1, Kim JH1, Planchard D1, Felip E1, Blackhall F1, Haggstrom D1, Yoh K1, Novello S1, Gold K1, Hirashima T1, Lin CC1, Mann H1, Cantarini M1, Ghiorghiu S1, Janne PA1.
View PubMed
-
Ann Oncol. 2017 Apr 1;28(4):874-881. doi: 10.1093/annonc/mdx008.
Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial
Hui R11, Garon EB2, Goldman JW2, Leighl NB3, Hellmann MD4, Patnaik A5, Gandhi L6, Eder JP7, Ahn MJ8, Horn L9, Felip E10, Carcereny E11, Rangwala R12, Lubiniecki GM12, Zhang J12, Emancipator K12, Roach C13, Rizvi NA14.
View PubMed
-
Cancer Discov. 2017 Apr;7(4):400-409. doi: 10.1158/2159-8290.CD-16-1237. Epub 2017 Feb 9.
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)
Drilon A11, Siena S2,3, Ou SI4, Patel M5, Ahn MJ6, Lee J6, Bauer TM7, Farago AF8, Wheler JJ9, Liu SV10, Doebele R11, Giannetta L2, Cerea G2, Marrapese G2, Schirru M2, Amatu A2, Bencardino K2, Palmeri L2, Sartore-Bianchi A2, Vanzulli A2,3, Cresta S12, Damian S12, Duca M12, Ardini E13, Li G14, Christiansen J14, Kowalski K14, Johnson AD14, Patel R14, Luo D14, Chow-Maneval E14, Hornby Z14, Multani PS14, Shaw AT8, De Braud FG3,12.
View PubMed
-
Support Care Cancer. 2017 Mar;25(3):801-809. doi: 10.1007/s00520-016-3463-0. Epub 2016 Nov 8.
Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types
Kim JE11, Jang JS2, Kim JW3, Sung YL4, Cho CH5, Lee MA6, Kim DJ7, Ahn MJ8, Lee KY9, Sym SJ10, Lim MC11, Jung H12, Cho EK12, Min KW12.
View PubMed
-
N Engl J Med. 2017 Feb 16;376(7):629-640. doi: 10.1056/NEJMoa1612674. Epub 2016 Dec 6.
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer
Mok TS11, Wu Y-L1, Ahn M-J1, Garassino MC1, Kim HR1, Ramalingam SS1, Shepherd FA1, He Y1, Akamatsu H1, Theelen WS1, Lee CK1, Sebastian M1, Templeton A1, Mann H1, Marotti M1, Ghiorghiu S1, Papadimitrakopoulou VA1; AURA3 Investigators.
View PubMed
-
Expert Opin Pharmacother. 2017 Feb;18(2):225-231. doi: 10.1080/14656566.2017.1285283.
Osimertinib for the treatment of non-small cell lung cancer
Sun JM11, Lee SH1, Ahn JS1, Park K1, Ahn MJ1.
View PubMed
-
Pathol Res Pract. 2017 Feb;213(2):106-112. doi: 10.1016/j.prp.2016.11.012. Epub 2016 Nov 15.
Histologic characteristics of thymic adenocarcinomas: Clinicopathologic study of a nine-case series and a review of the literature
Kwon AY11, Han J2, Chu J1, Choi YS3, Jeong BH4, Ahn MJ5, Ahn YC6.
View PubMed
-
RADIOTHERAPY AND ONCOLOGY, FEB 2017, 122(2):217-223, DOI: 10.1016/j.radonc.2016.09.015
A phase II trial of concurrent chemoradiotherapy with weekly docetaxel plus cisplatin treatment for unresectable locally advanced head and neck cancer
Lee JY1, Sun JM, Oh D, Lim SH, Chi S, Lee SH, Jung SH, Ahn MJ, Ahn YC, Park K
View PubMed
-
Oncotarget. 2017 Feb 28;8(9):15943-15951. doi: 10.18632/oncotarget.13056.
A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01)
Kim HR11, Jang JS2, Sun JM3, Ahn MJ3, Kim DW4, Jung I5, Lee KH6, Kim JH1, Lee DH7, Kim SW, Cho BC1.
View PubMed
-
Clin Lung Cancer. 2017 Jan;18(1):34-42.e2. doi: 10.1016/j.cllc.2016.07.007. Epub 2016 Aug 8.
Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations
Leighl NB11, Rizvi NA2, de Lima LG Jr3, Arpornwirat W4, Rudin CM5, Chiappori AA6, Ahn MJ7, Chow LQ8, Bazhenova L9, Dechaphunkul A10, Sunpaweravong P11, Eaton K12, Chen J13, Medley S13, Poondru S13, Singh M13, Steinberg J13, Juergens RA14, Gadgeel SM15.
View PubMed
-
J Stroke. 2017 Jan;19(1):77-87. doi: 10.5853/jos.2016.00570. Epub 2016 Dec 12.
Hypercoagulability and Mortality of Patients with Stroke and Active Cancer: The OASIS-CANCER Study
Lee MJ11, Chung JW1, Ahn MJ2, Kim S3, Seok JM1, Jang HM1, Kim GM1, Chung CS1, Lee KH1, Bang OY1.
View PubMed
-
Oncotarget. 2017 Jan 10;8(2):3542-3552. doi: 10.18632/oncotarget.12200.
Supraclavicular and/or celiac lymph node metastases from thoracic esophageal squamous cell carcinoma did not compromise survival following neoadjuvant chemoradiotherapy and surgery
Cho WK11, Oh D1, Ahn YC1, Shim YM2, Zo JI2, Sun JM3, Ahn MJ3, Park K3.
View PubMed
-
J Thorac Oncol. 2016 Dec;11(12):2051-2052. doi: 10.1016/j.jtho.2016.09.130.
Transient Asymptomatic Pulmonary Opacities during Osimertinib Treatment: "Stop or Go" Decision
Ahn MJ11, Sun JM2, Lee SH2, Ahn JS2, Park K2.
View PubMed
-
Lung Cancer. 2016 Dec;102:65-73. doi: 10.1016/j.lungcan.2016.10.011. Epub 2016 Oct 27.
Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial
Hanna NH11, Kaiser R2, Sullivan RN3, Aren OR4, Ahn MJ5, Tiangco B6, Voccia I7, Pawel JV8, Kovcin V9, Agulnik J10, Gaschler-Markefski B11, Barrueco J12, Sikken P11, Schloss C12, Kim JH13; LUME-Lung 2 Study group.
View PubMed
-
J Thorac Oncol. 2016 Dec;11(12):2202-2207. doi: 10.1016/j.jtho.2016.07.005. Epub 2016 Jul 14.
Do New pN Subclassifications Proposed by IASLC's Lung Cancer Staging Project Agree with ypN Categories after Trimodality Therapy for Initial N2 Disease?
Kim H11, Ahn YC2, Pyo H1, Oh D1, Noh JM1, Sun JM3, Ahn JS3, Ahn MJ3, Park K3, Choi YS4, Kim J4, Zo JI4, Shim YM4, Lee M5, Han J5.
View PubMed
-
Asia Pac J Clin Oncol. 2016 Dec;12(4):380-387. doi: 10.1111/ajco.12513. Epub 2016 Jun 17.
An East Asian subgroup analysis of PROCLAIM, a phase III trial of pemetrexed and cisplatin or etoposide and cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small cell lung cancer
Wang L11, Wu YL2, Lu S3, Deng L1, Ahn MJ4, Hsu FM5, Iscoe N6,7, Hossain A8, Puri T9, Zhang P10, Orlando M11.
View PubMed
-
Sci Transl Med. 2016 Dec 7;8(368):368ra172.
AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases
Yang Z11, Guo Q1, Wang Y1, Chen K1, Zhang L1, Cheng Z1, Xu Y1, Yin X1, Bai Y1, Rabbie S2, Kim DW3, Ahn MJ4, Yang JC5, Zhang X6.
View PubMed
-
BRITISH JOURNAL OF RADIOLOGY, 2016, 89(1067), DOI: 10.1259/bjr.20160109
Value of F-18-FDG heterogeneity for discerning metastatic from benign lymph nodes in nasopharyngeal carcinoma patients with suspected recurrence
Moon SH1, Cho YS, Son YI, Ahn YC, Ahn MJ, Choi JY, Kim BT, Lee KH
View PubMed
-
J Thorac Dis. 2016 Nov;8(11):3175-3186. doi: 10.21037/jtd.2016.11.25.
The impact of smoking status on radiologic tumor progression patterns and response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations
Cha YK11, Lee HY2, Ahn MJ3, Park K3, Ahn JS3, Sun JM3, Choi YL4, Lee KS2.
View PubMed
-
World Neurosurg. 2016 Nov;95:399-405. doi: 10.1016/j.wneu.2016.08.046. Epub 2016 Aug 24.
Outcomes of Gamma Knife Radiosurgery in Combination with Crizotinib for Patients with Brain Metastasis from Non-Small Cell Lung Cancer
Choi JW11, Kong DS1, Seol HJ1, Nam DH1, Yoo KH2, Sun JM2, Ahn JS2, Ahn MJ2, Park K2, Lee JI3.
View PubMed
-
Cancer. 2016 Oct;122(19):3024-31. doi: 10.1002/cncr.30135. Epub 2016 Jun 17.
Efficacy and Safety of Dovitinib in Pretreated Patients With Advanced Squamous Non-Small Cell Lung Cancer With FGFR1 Amplification: A Single-Arm, Phase 2 Study
Lim SH11, Sun JM1, Choi YL2, Kim HR3, Ahn S2, Lee JY1, Lee SH1, Ahn JS1, Park K1, Kim JH3, Cho BC4, Ahn MJ5.
View PubMed
-
TRANSLATIONAL CANCER RESEARCH, OCT 2016, 5:S629-S631, DOI: 10.21037/tcr.2016.10.40
Liquid biopsy in non-small cell lung cancer: come of age
1,Ahn MJ
View PubMed
-
Lung Cancer. 2016 Oct;100:24-29. doi: 10.1016/j.lungcan.2016.07.025. Epub 2016 Jul 26.
Value of volume-based early metabolic response in patients with unresectable thymic epithelial tumor
Moon SH11, Kim HS2, Cho YS1, Sun JM3, Ahn JS3, Park K3, Kim BT1, Ahn MJ4, Lee KH5.
View PubMed
-
Invest New Drugs. 2016 Aug;34(4):407-15. doi: 10.1007/s10637-016-0350-y. Epub 2016 Apr 5.
AZD9291 overcomes T790 M-mediated resistance through degradation of EGFR(L858R/T790M) in non-small cell lung cancer cells
Ku BM11, Bae YH1, Koh J1, Sun JM2, Lee SH2, Ahn JS2, Park K2, Ahn MJ3,4.
View PubMed
-
Med Oncol. 2016 Aug;33(8):97. doi: 10.1007/s12032-016-0811-3. Epub 2016 Jul 22.
Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis
Byeon S11, Ham JS1, Sun JM2, Lee SH2, Ahn JS2, Park K2, Ahn MJ3.
View PubMed
-
J Clin Oncol. 2016 Aug 20;34(24):2866-73. doi: 10.1200/JCO.2015.65.5936. Epub 2016 Jul 18.
Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2
Crino L11, Ahn MJ2, De Marinis F2, Groen HJ2, Wakelee H2, Hida T2, Mok T2, Spigel D2, Felip E2, Nishio M2, Scagliotti G2, Branle F2, Emeremni C2, Quadrigli M2, Zhang J2, Shaw AT2.
View PubMed
-
PLoS One. 2016 Jul 18;11(7):e0159170. doi: 10.1371/journal.pone.0159170. eCollection 2016.
Cancer Cell-Derived Extracellular Vesicles Are Associated with Coagulopathy Causing Ischemic Stroke via Tissue Factor-Independent Way: The OASIS-CANCER Study
Bang OY11,2, Chung JW1,2, Lee MJ1, Kim SJ1, Cho YH2,3, Kim GM1, Chung CS1, Lee KH1, Ahn MJ4, Moon GJ2,3.
View PubMed
-
Lung Cancer. 2016 Jun;96:48-51. doi: 10.1016/j.lungcan.2016.03.012. Epub 2016 Mar 26.
Assessment of objective responses in thymic epithelial tumors using ITMIG modified criteria
Kim HS11, Lee JY2, Lim SH2, Sun JM2, Lee SH2, Ahn JS2, Park K2, Ahn MJ3.
View PubMed
-
Oncotarget. 2016 Jun 14;7(24):36311-36320. doi: 10.18632/oncotarget.8904.
Targeted sequencing identifies genetic alterations that confer Primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium)
Lim SM11,2, Kim HR1, Cho EK3, Min YJ4, Ahn JS5, Ahn MJ5, Park K5, Cho BC1, Lee JH6, Jeong HC6, Kim EK6, Kim JH2.
View PubMed
-
Lung Cancer. 2016 Jun;96:56-62. doi: 10.1016/j.lungcan.2016.03.016. Epub 2016 Mar 29.
Outcomes of neoadjuvant concurrent chemoradiotherapy followed by surgery for non-small-cell lung cancer with N2 disease
Kim HK11, Cho JH1, Choi YS1, Zo JI1, Shim YM1, Park K2, Ahn MJ2, Ahn YC3, Kim K4, Kim J5.
View PubMed
-
Clin Cancer Res. 2016 May 1;22(9):2139-45. doi: 10.1158/1078-0432.CCR-15-1653. Epub 2015 Dec 14.
A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib
Lee JY11, Sun JM1, Lim SH1, Kim HS, Yoo KH1, Jung KS1, Song HN1, Ku BM2, Koh J2, Bae YH2, Lee SH1, Ahn JS1, Park K1, Ahn MJ3.
View PubMed
-
Head Neck. 2016 Apr;38 Suppl 1:E293-9. doi: 10.1002/hed.23988. Epub 2015 Jun 26.
Fate of patients with nasopharyngeal cancer who developed distant metastasis as first failure after definitive radiation therapy
Chang JH11,2, Ahn YC1, Park H1, Oh D1, Noh JM1, Sun JM3, Ahn MJ3, Park K3.
View PubMed
-
Cancer Res Treat. 2016 Apr;48(2):527-36. doi: 10.4143/crt.2015.249. Epub 2015 Sep 15.
Association between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma
Kim HS11, Lee JY1, Lim SH1, Park K1, Sun JM1, Ko YH2, Baek CH3, Son YI3, Jeong HS3, Ahn YC4, Lee MY5, Hong M6, Ahn MJ1.
View PubMed
-
Cancer Res Treat. 2016 Apr;48(2):458-64. doi: 10.4143/crt.2015.135. Epub 2015 Oct 14.
Tolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non-small Cell Lung Cancer: A Post Hoc Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial
Kang JH11, Ahn MJ2, Kim DW3, Cho EK4, Kim JH5, Shin SW6, Wang X7, Kim JS8, Orlando M9, Park K2.
View PubMed
-
Lancet. 2016 Apr 9;387(10027):1540-50. doi: 10.1016/S0140-6736(15)01281-7. Epub 2015 Dec 19.
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Herbst RS11, Baas P2, Kim DW3, Felip E4, Perez-Gracia JL5, Han JY6, Molina J7, Kim JH8, Arvis CD9, Ahn MJ10, Majem M11, Fidler MJ12, de Castro G Jr13, Garrido M14, Lubiniecki GM15, Shentu Y15, Im E15, Dolled-Filhart M15, Garon EB16.
View PubMed
-
Oncotarget. 2016 Mar 22;7(12):13797-809. doi: 10.18632/oncotarget.7318.
Integrated genomic approaches identify upregulation of SCRN1 as a novel mechanism associated with acquired resistance to erlotinib in PC9 cells harboring oncogenic EGFR mutation
Kim N11,2, Cho A2, Watanabe H3,4, Choi YL2,5, Aziz M6, Kassner M6, Joung JG7, Park AK1,2, Francis JM8, Bae JS7, Ahn SM5, Kim KM5, Park JO9, Park WY2,7, Ahn MJ9, Park K9, Koo J10, Yin HH6, Cho J1,2,7.
View PubMed
-
Oncotarget. 2016 Mar 22;7(12):14803-13. doi: 10.18632/oncotarget.7543.
The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma
Ku BM11, Yi SY2, Koh J1, Bae YH1, Sun JM3, Lee SH3, Ahn JS3, Park K3, Ahn MJ3.
View PubMed
-
EXPERT OPINION ON BIOLOGICAL THERAPY, MAR 3 2016, 16(3):397-406 , DOI: 10.1517/14712598.2016.1145652
Pembrolizumab for the treatment of non-small cell lung cancer
Lim SH1, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ
View PubMed
-
Cancer Imaging. 2016 Mar 16;16:5. doi: 10.1186/s40644-016-0063-7.
Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study
Lee JH11, Lee HY2, Ahn MJ3, Park K3, Ahn JS3, Sun JM3, Lee KS1.
View PubMed
-
J Clin Oncol. 2016 Feb 10;34(5):511-2. doi: 10.1200/JCO.2015.64.2496. Epub 2015 Dec 28.
Prognostic and Predictive Roles of Thymidylate Synthase Expression in Lung Cancer: The Debate Is Still Open Reply
Giovannetti E11, Zucali PA2, Rolfo C3, Assaraf YG4, Peters GJ5.
View PubMed
-
Oncotarget. 2016 Feb 9;7(6):6984-93. doi: 10.18632/oncotarget.6874.
Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)
Lee JY11, Qing X2, Xiumin W2, Yali B2, Chi S3, Bak SH4, Lee HY5, Sun JM1, Lee SH1, Ahn JS1, Cho EK6, Kim DW7, Kim HR8, Min YJ9, Jung SH3, Park K1, Mao M2, Ahn MJ1.
View PubMed
-
Oral Oncol. 2016 Feb;53:10-6. doi: 10.1016/j.oraloncology.2015.11.019. Epub 2015 Dec 19.
Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: A literature review
Ahn MJ11, D'Cruz A2, Vermorken JB3, Chen JP4, Chitapanarux I5, Dang HQ6, Guminski A7, Kannarunimit D8, Lin TY9, Ng WT10, Park KU11, Chan AT12.
View PubMed
-
Radiother Oncol. 2016 Feb;118(2):244-50. doi: 10.1016/j.radonc.2015.11.030. Epub 2015 Dec 17.
Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II trial (KCSG-HN10-02)
Lee JY11, Sun JM1, Oh DR2, Lim SH1, Goo J3, Lee SH1, Kim SB4, Park KU5, Kim HK6, Hong DS7, Kim JS8, Kim SG9, Yi SY10, Yun HJ11, Hyun MS12, Kim HJ13, Jung SH3, Park K1, Ahn YC14, Ahn MJ15.
View PubMed
-
Jpn J Clin Oncol. 2016 Jan;46(1):40-5. doi: 10.1093/jjco/hyv163. Epub 2015 Nov 10.
Different clinical outcomes between locally advanced hypopharyngeal and oropharyngeal cancer treated with definitive concurrent chemoradiotherapy: implication for subgroup selection for induction chemotherapy
Lim SH11, Lee SJ1, Ahn MJ1, Park K1, Sun JM2.
View PubMed
-
Eur J Cancer. 2016 Jan;52:1-9. doi: 10.1016/j.ejca.2015.09.019. Epub 2015 Nov 26.
Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer
Lim SH11, Hong M2, Ahn S3, Choi YL3, Kim KM3, Oh D4, Ahn YC4, Jung SH5, Ahn MJ1, Park K1, Zo JI6, Shim YM6, Sun JM7.
View PubMed
-
Cancer Res Treat. 2016 Jan;48(1):20-7. doi: 10.4143/crt.2014.317. Epub 2015 Mar 2.
Current Status and Challenges of Cancer Clinical Trials in Korea
Shim BY11, Park SH2, Lee S3, Kim JS4, Lee KE5, Kang YK6, Ahn MJ2.
View PubMed
-
Sci Rep. 2016 Jan 21;6:19552. doi: 10.1038/srep19552.
Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck
Huang KK11,2, Jang KW3, Kim S4, Kim HS5,6, Kim SM3, Kwon HJ7, Kim HR7, Yun HJ8, Ahn MJ9, Park KU10, Ramnarayanan K2, McPherson JR2,11, Zhang S2, Rhee JK12, Vettore AL2, Das K2, Ishimoto T2, Kim JH5, Koh YW13, Kim SH13, Choi EC13, Teh BT1,2,14, Rozen SG2,11, Kim TM12, Tan P1,2,15, Cho BC5.
View PubMed
-
Oncotarget. 2015 Dec 29;6(42):44971-84. doi: 10.18632/oncotarget.6056.
Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma
Kim HS11, Kim SM2, Kim H3, Pyo KH2, Sun JM4, Ahn MJ4, Park K4, Keam B5, Kwon NJ6, Yun HJ7, Kim HG8, Chung IJ9, Lee JS10, Lee KH11, Kim DJ12, Lee CG13, Hur J14, Chung H15, Park JC15, Shin SK15, Lee SK15, Kim HR1, Moon YW1, Lee YC15, Kim JH1, Paik S16,17, Cho BC1.
View PubMed
-
J Thorac Oncol. 2015 Dec;10(12):1800-6. doi: 10.1097/JTO.0000000000000692.
A Prospective Phase II Study of Cisplatin and Cremophor EL-Free Paclitaxel (Genexol-PM) in Patients with Unresectable Thymic Epithelial Tumors
Kim HS11, Lee JY, Lim SH, Sun JM, Lee SH, Ahn JS, Park K, Moon SH, Ahn MJ.
View PubMed
-
Lung Cancer. 2015 Nov;90(2):261-6. doi: 10.1016/j.lungcan.2015.08.020. Epub 2015 Sep 4.
Pemetrexed plus platinum versus pemetrexed alone in non-small cell lung cancer patients who have progressed after first-line EGFR TKIs
Lee SJ11, Sun JM1, Lee SH1, Ahn JS1, Park K1, Ahn MJ2.
View PubMed
-
J Neurooncol. 2015 Nov;125(2):331-8. doi: 10.1007/s11060-015-1915-x. Epub 2015 Sep 15.
Outcome of gamma knife radiosurgery for metastatic brain tumors derived from non-small cell lung cancer
Cho KR11, Lee MH1, Kong DS1, Seol HJ1, Nam DH1, Sun JM2, Ahn JS2, Ahn MJ2, Park K2, Kim ST3, Lim do H4, Lee JI5.
View PubMed
-
Ann Oncol. 2015 Oct;26(10):2066-72. doi: 10.1093/annonc/mdv288. Epub 2015 Jul 7.
A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)
Yoshioka H11, Azuma K2, Yamamoto N3, Takahashi T4, Nishio M5, Katakami N6, Ahn MJ7, Hirashima T8, Maemondo M9, Kim SW10, Kurosaki M11, Akinaga S11, Park K7, Tsai CM12, Tamura T13, Mitsudomi T14, Nakagawa K15.
View PubMed
-
Oncotarget. 2015 Oct 20;6(32):33358-68. doi: 10.18632/oncotarget.5188.
The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysis
Kim ST11, Lee J1, Hong M2,3, Park K4,5, Park JO1, Ahn T3,4, Park SH1, Park YS1, Lim HY1, Sun JM1, Ahn JS1, Ahn MJ1, Kim HC6, Sohn TS6, Choi DI7, Cho JH8, Heo JS6, Kwon W6, Uhm SW9, Lee H10, Min BH10, Hong SN10, Kim DH5,11, Jung SH12, Park W4,5, Kim KM2,3, Kang WK1, Park K1,2.
View PubMed
-
Cancer Res Treat. 2015 Oct;47(4):645-52. doi: 10.4143/crt.2014.144. Epub 2015 Feb 12.
Definitive Bimodality Concurrent Chemoradiotherapy in Patients with Inoperable N2-positive Stage IIIA Non-small Cell Lung Cancer
Noh JM11, Ahn YC1, Lee H2, Pyo H1, Kim B1, Oh D1, Park H1, Lee E1, Park K3, Ahn JS3, Ahn MJ3, Sun JM3.
View PubMed
-
ONCOTARGET, OCT 13 2015, 6(31), 30929-30938, 10.18632/oncotarget.5131
Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer
Park S1, Langley E, Sun JM, Lockton S, Ahn JS, Jain A, Park K, Singh S, Kim P, Ahn MJ
View PubMed
-
AJR Am J Roentgenol. 2015 Sep;205(3):623-8. doi: 10.2214/AJR.14.13847.
Volume-Based Assessment With F-18-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer
Hyun SH11, Ahn HK2, Ahn MJ3, Ahn YC4, Kim J5, Shim YM5, Choi JY1.
View PubMed
-
Lancet Oncol. 2015 Aug;16(8):990-8. doi: 10.1016/S1470-2045(15)00121-7. Epub 2015 Jul 6.
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation- positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
Soria JC11, Wu YL2, Nakagawa K3, Kim SW4, Yang JJ2, Ahn MJ5, Wang J6, Yang JC7, Lu Y8, Atagi S9, Ponce S10, Lee DH4, Liu Y11, Yoh K12, Zhou JY13, Shi X14, Webster A15, Jiang H14, Mok TS16.
View PubMed
-
J Clin Oncol. 2015 Aug 20;33(24):2660-6. doi: 10.1200/JCO.2014.60.0130. Epub 2015 Jul 6.
Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04
Ahn JS11, Ahn YC1, Kim JH1, Lee CG1, Cho EK1, Lee KC1, Chen M1, Kim DW1, Kim HK1, Min YJ1, Kang JH1, Choi JH1, Kim SW1, Zhu G1, Wu YL1, Kim SR1, Lee KH1, Song HS1, Choi YL1, Sun JM1, Jung SH1, Ahn MJ1, Park K2.
View PubMed
-
PLoS Genet. 2015 Aug 21;11(8):e1005467. doi: 10.1371/journal.pgen.1005467. eCollection 2015.
Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer
Ji JH11, Oh YL2, Hong M2, Yun JW3, Lee HW2, Kim D4, Ji Y4, Kim DH4, Park WY3, Shin HT3, Kim KM2, Ahn MJ5, Park K5, Sun JM5.
View PubMed
-
J Clin Oncol. 2015 Aug 1;33(22):2450-6. doi: 10.1200/JCO.2014.59.9324. Epub 2015 Jun 29.
Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non-Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial
Sun JM11, Ahn JS1, Jung SH1, Sun J1, Ha SY1, Han J1, Park K1, Ahn MJ2.
View PubMed
-
Cancer Res Treat. 2015 Jul;47(3):424-35. doi: 10.4143/crt.2013.266. Epub 2014 Sep 15.
Pemetrexed Continuation Maintenance in Patients with Nonsquamous Non-small Cell Lung Cancer: Review of Two East Asian Trials in Reference to PARAMOUNT
Yang JC11, Ahn MJ2, Nakagawa K3, Tamura T4, Barraclough H5, Enatsu S6, Cheng R7, Orlando M8.
View PubMed
-
J Clin Oncol. 2015 Jun 10;33(17):1881-8. doi: 10.1200/JCO.2014.59.0539. Epub 2015 Jan 26.
Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases
Costa DB11, Shaw AT2, Ou SH2, Solomon BJ2, Riely GJ2, Ahn MJ2, Zhou C2, Shreeve SM2, Selaru P2, Polli A2, Schnell P2, Wilner KD2, Wiltshire R2, Camidge DR2, Crin? L2.
View PubMed
-
Clin Exp Otorhinolaryngol. 2015 Jun;8(2):142-8. doi: 10.3342/ceo.2015.8.2.142. Epub 2015 May 13.
Prognostic Value of Volume-Based Positron Emission Tomography/Computed Tomography in Patients With Nasopharyngeal Carcinoma Treated With Concurrent Chemoradiotherapy
Moon SH11, Choi JY1, Lee HJ1, Son YI2, Baek CH2, Ahn YC3, Ahn MJ4, Park K4, Kim BT1.
View PubMed
-
Cancer Chemother Pharmacol. 2015 Jun;75(6):1229-36. doi: 10.1007/s00280-015-2740-9. Epub 2015 Apr 23.
A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test
Choi MK11, Hong JY, Chang WJ, Kim MJ, Kim SM, Jung HA, Do IG, Choi YL, Sun JM, Ahn JS, Park K, Ahn MJ.
View PubMed
-
J Thorac Oncol. 2015 Jun;10(6):903-9. doi: 10.1097/JTO.0000000000000535.
The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors
Lee JY11, Ku BM, Lim SH, Lee MY, Kim H, Kim M, Kim S, Jung HA, Sun JM, Ahn JS, Park K, Ahn MJ.
View PubMed
-
Clin Lung Cancer. 2015 May;16(3):228-36. doi: 10.1016/j.cllc.2014.11.002. Epub 2014 Nov 18.
Survival Outcome Assessed According to Tumor Burden and Progression Patterns in Patients With Epidermal Growth Factor Receptor Mutant Lung Adenocarcinoma Undergoing Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy
Cha YK11, Lee HY2, Ahn MJ3, Choi YL4, Lee JH1, Park K3, Lee KS1.
View PubMed
-
Ann Oncol. 2015 May;26(5):894-901. doi: 10.1093/annonc/mdv072. Epub 2015 Feb 26.
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)
Blumenschein GR Jr11, Smit EF2, Planchard D3, Kim DW4, Cadranel J5, De Pas T6, Dunphy F7, Udud K8, Ahn MJ9, Hanna NH10, Kim JH11, Mazieres J12, Kim SW13, Baas P14, Rappold E15, Redhu S15, Puski A16, Wu FS15, J?nne PA17.
View PubMed
-
N Engl J Med. 2015 May 21;372(21):2018-28. doi: 10.1056/NEJMoa1501824. Epub 2015 Apr 19.
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Garon EB11, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L; KEYNOTE-001 Investigators.
View PubMed
-
Head Neck. 2015 May;37(5):E66-9. doi: 10.1002/hed.23884. Epub 2015 Mar 29.
Presence of anaplastic lymphoma kinase translocation in sarcomatoid carcinoma of head and neck and treatment effect of crizotinib: A case series
Kim SM11, Kim MJ, Jung HA, Sun JM, Choi YL, Ko YH, Park K, Baek CH, Son YI, Ahn MJ.
View PubMed
-
World J Gastroenterol. 2015 Apr 14;21(14):4268-74. doi: 10.3748/wjg.v21.i14.4268.
Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma
Lee MY11, Jung KS1, Kim HS1, Lee JY1, Lim SH1, Kim M1, Jung HA1, Kim SM1, Sun JM1, Ahn MJ1, Lee J1, Park SH1, Yi SY1, Hwang IG1, Lee SC1, Ahn HK1, Lim DH1, Lee SI1, Park KW1.
View PubMed
-
World J Gastroenterol. 2015 Apr 14;21(14):4268-74. doi: 10.3748/wjg.v21.i14.4268.
Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma
Lee MY11, Jung KS1, Kim HS1, Lee JY1, Lim SH1, Kim M1, Jung HA1, Kim SM1, Sun JM1, Ahn MJ1, Lee J1, Park SH1, Yi SY1, Hwang IG1, Lee SC1, Ahn HK1, Lim do H1, Lee SI1, Park KW1.
View PubMed
-
N Engl J Med. 2015 Apr 30;372(18):1689-99. doi: 10.1056/NEJMoa1411817.
AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer
Janne PA11, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, Haggstrom D, Felip E, Kim JH, Frewer P, Cantarini M, Brown KH, Dickinson PA, Ghiorghiu S, Ranson M.
View PubMed
-
Ann Oncol. 2015 Apr;26(4):762-8. doi: 10.1093/annonc/mdu584. Epub 2014 Dec 23.
A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer
Lim SH11, Lee JY1, Lee MY1, Kim HS1, Lee J1, Sun JM1, Ahn JS1, Um SW2, Kim H2, Kim BS3, Kim ST4, Na DL5, Sun JY6, Jung SH7, Park K1, Kwon OJ2, Lee JI3, Ahn MJ8.
View PubMed
-
Pharmacogenomics. 2015;16(4):383-91. doi: 10.2217/pgs.15.14.
Correlation of genetic polymorphisms with clinical outcomes in pemetrexed-treated advanced lung adenocarcinoma patients
Woo HI11, Kim JA, Jung HA, Kim KK, Lee JY, Sun JM, Ahn JS, Park K, Lee SY, Ahn MJ.
View PubMed
-
Lung Cancer. 2015 Feb;87(2):148-54. doi: 10.1016/j.lungcan.2014.11.013. Epub 2014 Nov 29.
Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: A retrospective analysis in Korea
Baek JH11, Sun JM2, Min YJ3, Cho EK4, Cho BC5, Kim JH5, Ahn MJ2, Park K2.
View PubMed
-
J Thorac Oncol. 2015 Feb;10(2):331-7. doi: 10.1097/JTO.0000000000000388.
Endobronchial Ultrasound versus Mediastinoscopy for Mediastinal Nodal Staging of Non-Small-Cell Lung Cancer
Um SW11, Kim HK, Jung SH, Han J, Lee KJ, Park HY, Choi YS, Shim YM, Ahn MJ, Park K, Ahn YC, Choi JY, Lee KS, Suh GY, Chung MP, Kwon OJ, Kim J, Kim H.
View PubMed
-
Clin Cancer Res. 2015 Feb 1;21(3):544-52. doi: 10.1158/1078-0432.CCR-14-1756. Epub 2014 Nov 25.
Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck
Kim HS11, Kwon HJ2, Jung I3, Yun MR4, Ahn MJ5, Kang BW6, Sun JM5, Kim SB7, Yoon DH7, Park KU8, Lee SH9, Koh YW10, Kim SH10, Choi EC10, Koo DH11, Sohn JH12, Kim B13, Kwon NJ14, Yun HJ15, Lee MG16, Lee JH17, Kim TM18, Kim HR19, Kim JH19, Paik S20, Cho BC21.
View PubMed
-
Invest New Drugs. 2015 Feb;33(1):12-21. doi: 10.1007/s10637-014-0163-9. Epub 2014 Oct 25.
BYL719, a selective inhibitor of phosphoinositide 3-Kinase alpha, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer
Ku BM11, Jho EH, Bae YH, Sun JM, Ahn JS, Park K, Ahn MJ.
View PubMed
-
Ann Oncol. 2015 Jan;26(1):161-6. doi: 10.1093/annonc/mdu504. Epub 2014 Oct 29.
Small-cell lung cancer detection in never-smokers: clinical characteristics and multigene mutation profiling using targeted next-generation sequencing
Sun JM11, Choi YL2, Ji JH3, Ahn JS1, Kim KM2, Han J2, Ahn MJ1, Park K4.
View PubMed
-
J Thorac Oncol. 2014 Oct;9(10):1523-31. doi: 10.1097/JTO.0000000000000275.
Safety and Efficacy of Dacomitinib in Korean Patients with KRAS Wild-Type Advanced Non-Small-Cell Lung Cancer Refractory to Chemotherapy and Erlotinib or Gefitinib A Phase I/II Trial
Park K11, Cho BC, Kim DW, Ahn MJ, Lee SY, Gernhardt D, Taylor I, Campbell AK, Zhang H, Giri N, Letrent SP, O'Connell J, Heo DS.
View PubMed
-
J Transl Med. 2014 Oct 25;12:299. doi: 10.1186/s12967-014-0299-6.
High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma
Ku BM1, Jung HA, Sun JM, Ko YH, Jeong HS, Son YI, Baek CH, Park K, Ahn MJ.
View PubMed
-
Eur J Cancer. 2014 Sep;50(13):2219-30. doi: 10.1016/j.ejca.2014.05.011. Epub 2014 Jun 18.
First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial
Yang JC11, Kang JH2, Mok T3, Ahn MJ4, Srimuninnimit V5, Lin CC1, Kim DW6, Tsai CM7, Barraclough H8, Altug S9, Orlando M10, Park K11.
View PubMed
-
Oncologist. 2014 Jul;19(7):702-3. doi: 10.1634/theoncologist.2013-0419. Epub 2014 May 27.
Phase II Study of Afatinib as Third-Line Treatment for Patients in Korea With Stage IIIB/IV Non-Small Cell Lung Cancer Harboring Wild-Type EGFR
Ahn MJ11, Kim SW2, Cho BC3, Ahn JS1, Lee DH2, Sun JM1, Massey D4, Kim M5, Shi Y6, Park K7.
View PubMed
-
Cancer Chemother Pharmacol. 2014 Jun;73(6):1217-25. doi: 10.1007/s00280-014-2458-0. Epub 2014 Apr 3.
Safety and efficacy of gemcitabine or pemetrexed in combination with a platinum in patients with non-small-cell lung cancer and prior interstitial lung disease
Choi MK11, Hong JY, Chang W, Kim M, Kim S, Jung HA, Lee SJ, Park S, Chung MP, Sun JM, Park K, Ahn MJ, Ahn JS.
View PubMed
-
Ann Surg Oncol. 2014 Jun;21(6):2083-90. doi: 10.1245/s10434-014-3540-x. Epub 2014 Feb 13.
Pretreatment Clinical Mediastinal Nodal Bulk and Extent do not Influence Survival in N2-Positive Stage IIIA Non-small Cell Lung Cancer Patients Treated with Trimodality Therapy
Lee H11, Ahn YC, Pyo H, Kim B, Oh D, Nam H, Lee E, Sun JM, Ahn JS, Ahn MJ, Park K, Choi YS, Kim J, Zo JI, Shim YM.
View PubMed
-
Cancer Chemother Pharmacol.?2014 May;73(5):1063-70. doi: 10.1007/s00280-014-2442-8. Epub 2014 Mar 25.
Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs
Lee JY11,?Lim SH,?Kim M,?Kim S,?Jung HA,?Chang WJ,?Choi MK,?Hong JY,?Lee SJ,?Sun JM,?Ahn JS,?Park K,?Ahn MJ.
View PubMed
-
Ann Oncol. 2014 May;25(5):1044-52. doi: 10.1093/annonc/mdu098. Epub 2014 Feb 27.
Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial
Barlesi F11, Scherpereel A, Gorbunova V, Gervais R, Vikstr?m A, Chouaid C, Chella A, Kim JH, Ahn MJ, Reck M, Pazzola A, Kim HT, Aerts JG, Morando C, Loundou A, Groen HJ, Rittmeyer A.
View PubMed
-
Lung Cancer. 2014 Apr;84(1):51-5. doi: 10.1016/j.lungcan.2014.01.017. Epub 2014 Jan 28.
A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): Paclitaxel plus carboplatin versus vinorelbine plus cisplatin
Chang WJ11, Sun JM2, Lee JY1, Ahn JS1, Ahn MJ1, Park K1.
View PubMed
-
J Thorac Oncol. 2014 Apr;9(4):506-11. doi: 10.1097/JTO.0000000000000095.
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non-Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor Receptor Mutation in Either Exon 19 or 21
Lim SH11, Lee JY, Sun JM, Ahn JS, Park K, Ahn MJ.
View PubMed
-
CANCER IMAGING, APR 22 2014, 14, 10.1186/1470-7330-14-2
Prognostic value of volumetric metabolic parameters measured by [F-18]Fluorodeoxyglucose-positron emission tomography/computed tomography in patients with small cell lung cancer
Park1, SB, Choi, JY, Moon, SH, Yoo, J, Kim, H, Ahn, YC, Ahn, MJ, Park, K, Kim, BT
View PubMed
-
J Mol Diagn. 2014 Mar;16(2):229-43. doi: 10.1016/j.jmoldx.2013.11.007. Epub 2014 Jan 10.
A Single-Tube Multiplexed Assay for Detecting ALK, ROS1, and RET Fusions in Lung Cancer
Lira ME11, Choi YL2, Lim SM3, Deng S1, Huang D1, Ozeck M1, Han J4, Jeong JY5, Shim HS5, Cho BC3, Kim J6, Ahn MJ7, Mao M8.
View PubMed
-
PLoS One. 2014 Feb 26;9(2):e88598. doi: 10.1371/journal.pone.0088598. eCollection 2014.
Quantitative CT Variables Enabling Response Prediction in Neoadjuvant Therapy with EGFR-TKIs: Are They Different from Those in Neoadjuvant Concurrent Chemoradiotherapy
Chong Y11, Kim JH1, Lee HY1, Ahn YC2, Lee KS1, Ahn MJ3, Kim J4, Shim YM4, Han J5, Choi YL5.
View PubMed
-
When the Abstract Reports a Well-Tolerated Treatment, the Data Should Support It Reply
-
Lung Cancer. 2014 Feb;83(2):259-64. doi: 10.1016/j.lungcan.2013.11.009. Epub 2013 Nov 20.
Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma
Sun JM11, Lira M2, Pandya K2, Choi YL3, Ahn JS1, Mao M2, Han J3, Park K1, Ahn MJ4, Kim J5.
View PubMed
-
Anticancer Res. 2014 Feb;34(2):707-14.
Assessment of Intratumoral Heterogeneity of Oncogenic Driver Mutations in Surgically-resected Lung Adenocarcinoma: Implications of Percutaneous Biopsy-based Molecular Assay for Target-directed Therapy
Kim HK11, Lee HY, Choi YL, Choi SJ, Choi H, Lee J, Han J, Ahn MJ, Lee KS, Kim J.
View PubMed
-
Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):50-8. doi: 10.1007/s00259-013-2530-8. Epub 2013 Aug 16.
Volume-based assessment by F-18-FDG PET/CT predicts survival in patients with stage III non-small-cell lung cancer
Hyun SH11, Ahn HK, Kim H, Ahn MJ, Park K, Ahn YC, Kim J, Shim YM, Choi JY.
View PubMed
-
J Clin Oncol. 2014 Jan 10;32(2):121-8. doi: 10.1200/JCO.2013.50.8556. Epub 2013 Dec 9.
Integrative and Comparative Genomic Analysis of Lung Squamous Cell Carcinomas in East Asian Patients
Kim Y11, Hammerman PS, Kim J, Yoon JA, Lee Y, Sun JM, Wilkerson MD, Pedamallu CS, Cibulskis K, Yoo YK, Lawrence MS, Stojanov P, Carter SL, McKenna A, Stewart C, Sivachenko AY, Oh IJ, Kim HK, Choi YS, Kim K, Shim YM, Kim KS, Song SY, Na KJ, Choi YL, Hayes DN, Kim J, Cho S, Kim YC, Ahn JS, Ahn MJ, Getz G, Meyerson M, Park K.
View PubMed
-
Lung Cancer. 2013 Dec;82(3):455-60. doi: 10.1016/j.lungcan.2013.08.027. Epub 2013 Sep 8.
A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy
Ahn JS11, Lee KH, Sun JM, Park K, Kang ES, Cho EK, Lee DH, Kim SW, Lee GW, Kang JH, Lee JS, Lee JW, Ahn MJ.
View PubMed
-
Cancer Res Treat.?2013 Dec;45(4):343-8. doi: 10.4143/crt.2013.45.4.343. Epub 2013 Dec 31.
Tumor Lysis Syndrome in a Solid Tumor: A Case Report of a Patient with Invasive Thymoma
Lee JY11,?Lim SH1,?Lee JY1,?Kim JH1,?Choi KH1,?Park K1,?Sun JM1,?Ahn JS1,?Ahn MJ1.
View PubMed
-
J Thorac Oncol. 2013 Nov;8(11):1409-16. doi: 10.1097/JTO.0b013e3182a46bcf.
Health-Related Quality of Life in Patients with Advanced Nonsquamous Non-Small-Cell Lung Cancer Receiving Bevacizumab or Bevacizumab-Plus-Pemetrexed Maintenance Therapy in AVAPERL (MO22089)
Rittmeyer A11, Gorbunova V, Vikstr?m A, Scherpereel A, Kim JH, Ahn MJ, Chella A, Chouaid C, Campbell AK, Barlesi F.
View PubMed
-
Anticancer Res.?2013 Nov;33(11):5127-33.
High-throughput Molecular Genotyping for Small Biopsy Samples in Advanced Non-small Cell Lung Cancer Patients
Maeng CH11,?Lee HY,?Kim YW,?Choi MK,?Hong JY,?Jung HA,?Lee KS,?Kim H,?Kwon OJ,?Sun JM,?Ahn JS,?Park K,?Um SW,?Ahn MJ.
View PubMed
-
J Clin Oncol. 2013 Aug 20;31(24):3004-11. doi: 10.1200/JCO.2012.42.3749. Epub 2013 Jul 8.
Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: AVAPERL (MO22089)
Barlesi F11, Scherpereel A, Rittmeyer A, Pazzola A, Ferrer Tur N, Kim JH, Ahn MJ, Aerts JG, Gorbunova V, Vikstrom A, Wong EK, Perez-Moreno P, Mitchell L, Groen HJ.
View PubMed
-
Eur J Nucl Med Mol Imaging. 2013 Jul;40(7):1005-13. doi: 10.1007/s00259-013-2400-4. Epub 2013 Apr 18.
Metabolic response evaluated by F-18-FDG PET/CT as a potential screening tool in identifying a subgroup of patients with advanced non-small cell lung cancer for immediate maintenance therapy after first-line chemotherapy
Moon SH11, Cho SH, Park LC, Ji JH, Sun JM, Ahn JS, Park K, Choi JY, Ahn MJ.
View PubMed
-
Ann Oncol. 2013 Jun;24(6):1630-9. doi: 10.1093/annonc/mds649. Epub 2013 Feb 7.
Prospective analysis of quality of life in elderly patients treated with adjuvant chemotherapy for non-small-celll lung cancer
Park S11, Kim IR, Baek KK, Lee SJ, Chang WJ, Maeng CH, Hong JY, Choi MK, Kim YS, Sun JM, Ahn JS, Park K, Jo J, Jung SH, Ahn MJ.
View PubMed
-
N Engl J Med. 2015 Oct 15;373(16):1582. doi: 10.1056/NEJMx150036.
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
1,[No authors listed]
View PubMed
-
Lung Cancer. 2013 Mar;79(3):300-6. doi: 10.1016/j.lungcan.2012.11.010. Epub 2012 Dec 21.
Epidermal growth factor receptor mutation and treatment outcome of mediastinoscopic N2 positive non-small cell lung cancer patients treated with neoadjuvant chemoradiotherapy followed by surgery
Ahn HK11, Choi YL, Han JH, Ahn YC, Kim K, Kim J, Shim YM, Um SW, Kim H, Kwon OJ, Sun JM, Ahn JS, Park K, Ahn MJ.
View PubMed
-
J Thorac Oncol. 2013 Mar;8(3):373-84. doi: 10.1097/JTO.0b013e31827ed0ff.
Epidermal Growth Factor Receptor Inhibition in Lung Cancer Status 2012
Hirsch FR11, Janne PA, Eberhardt WE, Cappuzzo F, Thatcher N, Pirker R, Choy H, Kim ES, Paz-Ares L, Gandara DR, Wu YL, Ahn MJ, Mitsudomi T, Shepherd FA, Mok TS.
View PubMed
-
Med Oncol. 2013 Mar;30(1):479. doi: 10.1007/s12032-013-0479-x. Epub 2013 Feb 3.
Clinical outcomes of atypical carcinoid tumors of the lung and thymus: 7-year experience of a rare malignancy at single institute
Han B11, Sun JM, Ahn JS, Park K, Ahn MJ.
View PubMed
-
J Thorac Oncol. 2013 Feb;8(2):185-91. doi: 10.1097/JTO.0b013e3182773f21.
Leptomeningeal Carcinomatosis in Non-Small-Cell Lung Cancer Patients Impact on Survival and Correlated Prognostic Factors
Lee SJ11, Lee JI, Nam DH, Ahn YC, Han JH, Sun JM, Ahn JS, Park K, Ahn MJ.
View PubMed
-
J Mol Diagn. 2013 Jan;15(1):51-61. doi: 10.1016/j.jmoldx.2012.08.006. Epub 2012 Dec 12.
Multiplexed Gene Expression and Fusion Transcript Analysis to Detect ALK Fusions in Lung Cancer
Lira ME11, Kim TM, Huang D, Deng S, Koh Y, Jang B, Go H, Lee SH, Chung DH, Kim WH, Schoenmakers EF, Choi YL, Park K, Ahn JS, Sun JM, Ahn MJ, Kim DW, Mao M.
View PubMed
-
Lung Cancer. 2013 Jan;79(1):40-5. doi: 10.1016/j.lungcan.2012.10.002. Epub 2012 Oct 25.
Favorable clinical outcomes of pemetrexed treatment in anaplastic lymphoma kinase positive non-small-cell lung cancer
Lee HY11, Ahn HK, Jeong JY, Kwon MJ, Han JH, Sun JM, Ahn JS, Park K, Choi YL, Ahn MJ.
View PubMed
-
Cancer. 2012 Dec 15;118(24):6234-42. doi: 10.1002/cncr.27630. Epub 2012 Jun 6.
Gefitinib Versus Pemetrexed as Second-Line Treatment in Patients With Nonsmall Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy (KCSG-LU08-01)
Sun JM11, Lee KH, Kim SW, Lee DH, Min YJ, Yun HJ, Kim HK, Song HS, Kim YH, Kim BS, Hwang IG, Lee K, Jo SJ, Lee JW, Ahn JS, Park K, Ahn MJ; Korean Cancer Study Group.
View PubMed
-
Eur J Cancer. 2012 Nov;48(17):3198-204. doi: 10.1016/j.ejca.2012.06.009. Epub 2012 Jul 13.
A prospective multicentre phase II study of cisplatin and weekly docetaxel as first-line treatment for recurrent or metastatic nasopharyngeal cancer (KCSG HN07-01)
Ji JH1; Korean Cancer Study Group (KCSG)1, Yun T, Kim SB, Kang JH, Park JC, Cho IS, Sohn CH, Heo DS, Jang JS, Shin SW, Hwang DW, Sun JM, Park K, Ahn MJ.
View PubMed
-
Cancer Chemother Pharmacol. 2012 Aug;70(2):315-20. doi: 10.1007/s00280-012-1876-0. Epub 2012 Jul 4.
Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation
Cho SH11, Park LC, Ji JH, Park S, Hwang DW, Lee JY, Choi YL, Han JH, Sun JM, Ahn JS, Park K, Ahn MJ.
View PubMed
-
Lung Cancer. 2012 Aug;77(2):346-52. doi: 10.1016/j.lungcan.2012.03.011. Epub 2012 Apr 23.
Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer
Ahn MJ11, Yang JC, Liang J, Kang JH, Xiu Q, Chen YM, Blair JM, Peng G, Linn C, Orlando M.
View PubMed
-
J Oral Pathol Med. 2012 May;41(5):415-23. doi: 10.1111/j.1600-0714.2011.01105.x. Epub 2011 Nov 14.
Reappraisal of KIT mutation in adenoid cystic carcinomas of the salivary gland
Sung JY11, Ahn HK, Kwon JE, Jeong H, Baek CH, Son YI, Ahn YC, Park K, Ahn MJ, Ko YH.
View PubMed
-
J Clin Oncol. 2012 Apr 1;30(10):1122-8. doi: 10.1200/JCO.2011.36.8456. Epub 2012 Feb 27.
First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung
Han JY11, Park K, Kim SW, Lee DH, Kim HY, Kim HT, Ahn MJ, Yun T, Ahn JS, Suh C, Lee JS, Yoon SJ, Han JH, Lee JW, Jo SJ, Lee JS.
View PubMed
-
Hum Genet.?2012 Mar;131(3):365-72. doi: 10.1007/s00439-011-1080-z. Epub 2011 Aug 25.
The 18p11.22 locus is associated with never smoker non-small cell lung cancer susceptibility in Korean populations
Ahn MJ11,?Won HH,?Lee J,?Lee ST,?Sun JM,?Park YH,?Ahn JS,?Kwon OJ,?Kim H,?Shim YM,?Kim J,?Kim K,?Kim YH,?Park JY,?Kim JW,?Park K.
View PubMed
-
Lung Cancer. 2012 Jan;75(1):82-8. doi: 10.1016/j.lungcan.2011.05.022.
Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy
Kim ST11, Uhm JE, Lee J, Sun JM, Sohn I, Kim SW, Jung SH, Park YH, Ahn JS, Park K, Ahn MJ.
View PubMed
-
J Cancer Res Clin Oncol. 2011 Aug;137(8):1203-11. doi: 10.1007/s00432-011-0986-0. Epub 2011 May 28.
Molecular profiles of EGFR, K-ras, c-met, and FGFR in pulmonary pleomorphic carcinoma, a rare lung malignancy
Lee S11, Kim Y, Sun JM, Choi YL, Kim JG, Shim YM, Park YH, Ahn JS, Park K, Han JH, Ahn MJ.
View PubMed
-
Oral Oncol. 2011 Aug;47(8):714-9. doi: 10.1016/j.oraloncology.2011.06.007. Epub 2011 Jun 25.
Insulin-like growth factor binding protein-3, in association with IGF-1 receptor, can predict prognosis in squamous cell carcinoma of the head and neck
Sun JM11, Jun HJ, Ko YH, Park YH, Ahn YC, Son YI, Baek JH, Park K, Ahn MJ.
View PubMed
-
Cancer Chemother Pharmacol. 2011 Aug;68(2):531-8. doi: 10.1007/s00280-010-1522-7. Epub 2010 Nov 25.
Safety and pharmacokinetics of intrathecal administration of pemetrexed in rats
Sun JM11, Nam MH, Chung JY, Im B, Lee SY, Suh YL, Ahn JS, Park K, Ahn MJ.
View PubMed
-
J Thorac Oncol. 2011 Aug;6(8):1392-9. doi: 10.1097/JTO.0b013e3182208ea8.
Significance of Thymidylate Synthase and Thyroid Transcription Factor 1 Expression in Patients with Nonsquamous Non-small Cell Lung Cancer Treated with Pemetrexed-Based Chemotherapy
Sun JM11, Han J, Ahn JS, Park K, Ahn MJ.
View PubMed
-
Lung?Cancer.?2011 Jul;73(1):63-9. doi: 10.1016/j.lungcan.2010.10.019. Epub 2010 Nov 18.
New CT response criteria in non-small cell lung cancer: Proposal and application in EGFR tyrosine kinase inhibitor therapy
Lee HY11,?Lee KS,?Ahn MJ,?Hwang HS,?Lee JW,?Park K,?Ahn JS,?Kim TS,?Yi CA,?Chung MJ.
View PubMed
-
Asia Pac J Clin Oncol. 2011 Jun;7 Suppl 2:13-21. doi: 10.1111/j.1743-7563.2011.01398.x.
An indirect comparison of bevacizumab plus cisplatin-gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced first-line non-squamous non-small cell lung cancer in East Asia
Chang JW11, Thongprasert S, Wright E, Tsang K, Kim HT, Ahn MJ, Kim JH, Kang JH, Kim SW, Walzer S.
View PubMed
-
Asia Pac J Clin Oncol. 2011 Jun;7 Suppl 2:22-33. doi: 10.1111/j.1743-7563.2011.01399.x.
Cost-effectiveness of bevacizumab-based therapy versus cisplatin plus pemetrexed for the first-line treatment of advanced non-squamous NSCLC in Korea and Taiwan
Ahn MJ11, Tsai CM, Hsia TC, Wright E, Chang JW, Kim HT, Kim JH, Kang JH, Kim SW, Bae EJ, Kang M, Lister J, Walzer S.
View PubMed
-
Asia Pac J Clin Oncol. 2011 Jun;7 Suppl 2:34-40. doi: 10.1111/j.1743-7563.2011.01400.x.
Comparative effectiveness of bevacizumab plus cisplatin-based chemotherapy versus pemetrexed plus cisplatin treatment in East Asian non-squamous non-small cell lung cancer patients applying real-life outcomes
Chang GC11, Ahn MJ, Wright E, Kim HT, Kim JH, Kang JH, Kim SW, Sherman S, Walzer S.
View PubMed
-
J Cancer Res Clin Oncol. 2011 Apr;137(4):687-94. doi: 10.1007/s00432-010-0928-2. Epub 2010 Jun 16.
The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients
Sun JM11, Won YW, Kim ST, Kim JH, Choi YL, Lee J, Park YH, Ahn JS, Park K, Ahn MJ.
View PubMed
-
Cancer. 2011 Jan 1;117(1):143-51. doi: 10.1002/cncr.25560. Epub 2010 Aug 27.
Clinical Impact of Amphiregulin Expression in Patients With Epidermal Growth Factor Receptor (EGFR) Wild-Type Nonsmall Cell Lung Cancer Treated With EGFR-Tyrosine Kinase Inhibitors
Chang MH11, Ahn HK, Lee J, Jung CK, Choi YL, Park YH, Ahn JS, Park K, Ahn MJ.
View PubMed
-
Oncology. 2010;79(1-2):78-84. doi: 10.1159/000320190. Epub 2010 Nov 12.
Prognostic Model to Predict Outcomes in Non-Small Cell Lung Cancer Patients with Erlotinib as Salvage Treatment
Kim ST11, Lee J, Sun JM, Park YH, Ahn JS, Park K, Ahn MJ.
View PubMed
-
Lung Cancer. 2010 Sep;69(3):330-6. doi: 10.1016/j.lungcan.2009.11.015. Epub 2009 Dec 14.
Unsuspected pulmonary emboli in lung cancer patients: The impact on survival and the significance of anticoagulation therapy
Sun JM11, Kim TS, Lee J, Park YH, Ahn JS, Kim H, Kwon OJ, Lee KS, Park K, Ahn MJ.
View PubMed
-
J Thorac Oncol.?2010 Aug;5(8):1185-96. doi: 10.1097/JTO.0b013e3181e2f624.
Korean Ethnicity as Compared with White Ethnicity Is an Independent Favorable Prognostic Factor for Overall Survival in Non-small Cell Lung Cancer before and after the Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Era
Ahn MJ11,?Lee J,?Park YH,?Ahn JS,?Ziogas A,?Zell JA,?Park K,?Ou SH.
View PubMed
-
Lung Cancer. 2010 Jul;69(1):105-9. doi: 10.1016/j.lungcan.2009.09.014. Epub 2009 Dec 2.
Accuracy of RECIST 1.1 for non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors
Sun JM11, Ahn MJ, Park MJ, Yi JH, Kim TS, Chung MJ, Park YH, Ahn JS, Park K.
View PubMed
-
Cancer. 2010 Jun 15;116(12):3025-33. doi: 10.1002/cncr.25130.
Comparison of Gefitinib Versus Erlotinib in Patients With Nonsmall Cell Lung Cancer Who Failed Previous Chemotherapy
Kim ST11, Lee J, Kim JH, Won YW, Sun JM, Yun J, Park YH, Ahn JS, Park K, Ahn MJ.
View PubMed
-
Lung?Cancer.?2010 May;68(2):258-63. doi: 10.1016/j.lungcan.2009.06.008. Epub 2009 Jul 9.
Can upfront systemic chemotherapy replace stereotactic radiosurgery or whole brain radiotherapy in the treatment of non-small cell lung cancer patients with asymptomatic brain metastases
Kim KH11,?Lee J,?Lee JI,?Nam do H,?Kong DS,?Ahn YC,?Park HC,?Kwon OJ,?Kim H,?Chang MH,?Yi SY,?Ji SH,?Park YH,?Ahn JS,?Park K,?Ahn MJ.
View PubMed
-
Cancer. 2010 Feb 1;116(3):676-85. doi: 10.1002/cncr.24748.
Clinical Impact of Phosphorylated Signal Transducer and Activator of Transcription 3, Epidermal Growth Factor Receptor, p53, and Vascular Endothelial Growth Factor Receptor I Expression in Resected Adenocarcinoma of Lung by Using Tissue Microarray
Kim HS11, Park YH, Lee J, Ahn JS, Kim J, Shim YM, Kim JH, Park K, Han J, Ahn MJ.
View PubMed
-
Cancer. 2010 Jan 1;116(1):132-6. doi: 10.1002/cncr.24719.
Multicenter Phase 2 Study of Belotecan, a New Camptothecin Analog, and Cisplatin for Chemotherapy-Naive Patients With Extensive-Disease Small Cell Lung Cancer
Lee DH11, Kim SW, Suh C, Lee JS, Ahn JS, Ahn MJ, Park K, Na II, Lee JC, Ryoo BY, Yang SH.
View PubMed
-
APMIS.?2009 Dec;117(12):861-9. doi: 10.1111/j.1600-0463.2009.02545.x.
Prognostic role of insulin-like growth factor receptor-1 expression in small cell lung cancer
Chang MH11,?Lee J,?Han J,?Park YH,?Ahn JS,?Park K,?Ahn MJ.
View PubMed
-
Med Oncol. 2009;26(3):287-91. doi: 10.1007/s12032-008-9117-4. Epub 2008 Nov 7.
The role of palliative chemotherapy for advanced pulmonary pleomorphic carcinoma
Hong JY11, Choi MK, Uhm JE, Park MJ, Lee J, Park YH, Ahn JS, Park K, Han JH, Ahn MJ.
View PubMed
-
J Biol Chem. 2009 Jul 24;284(30):20099-110. doi: 10.1074/jbc.M109.010017. Epub 2009 Jun 1.
House Dust Mite Allergen Der f 2-induced Phospholipase D1 Activation Is Critical for the Production of Interleukin-13 through Activating Transcription Factor-2 Activation in Human Bronchial Epithelial Cells
Park SY11, Cho JH, Oh DY, Park JW, Ahn MJ, Han JS, Oh JW.
View PubMed
-
J Thorac Oncol. 2009 Jul;4(7):809-15. doi: 10.1097/JTO.0b013e3181a94af4.
Discordance of Molecular Biomarkers Associated with Epidermal Growth Factor Receptor Pathway between Primary Tumors and Lymph Node Metastasis in Non-small Cell Lung Cancer
Park S11, Holmes-Tisch AJ, Cho EY, Shim YM, Kim J, Kim HS, Lee J, Park YH, Ahn JS, Park K, Janne PA, Ahn MJ.
View PubMed
-
Anticancer Res. 2009 May;29(5):1817-22.
Clinicopathological Implications of EpCAM Expression in Adenocarcinoma of the Lung
Kim Y11, Kim HS, Cui ZY, Lee HS, Ahn JS, Park CK, Park K, Ahn MJ.
View PubMed
-
Cancer.?2009 Apr 1;115(7):1518-30. doi: 10.1002/cncr.24151.
Prognostic Model to Predict Outcomes in Nonsmall Cell Lung Cancer Patients Treated With Gefitinib as a Salvage Treatment
Park MJ11,?Lee J,?Hong JY,?Choi MK,?Yi JH,?Lee SJ,?Oh SJ,?Ahn JS,?Park K,?Ahn MJ.
View PubMed
-
Oncology. 2009;76(4):239-46. doi: 10.1159/000205386. Epub 2009 Feb 25.
Comparison of Survival in Advanced Non-Small Cell Lung Cancer Patients in the Pre- and Post-Gefitinib Eras
Kim HS11, Park K, Jun HJ, Yi SY, Lee J, Ahn JS, Park YH, Kim S, Lee S, Ahn MJ.
View PubMed
-
Cancer. 2008 Sep 15;113(6):1379-86. doi: 10.1002/cncr.23693.
ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy
Hwang IG11, Ahn MJ, Park BB, Ahn YC, Han J, Lee S, Kim J, Shim YM, Ahn JS, Park K.
View PubMed
-
Clin Cancer Res. 2008 Jun 15;14(12):3860-6. doi: 10.1158/1078-0432.CCR-07-4608.
Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer
Ahn MJ11, Park BB, Ahn JS, Kim SW, Kim HT, Lee JS, Kang JH, Cho JY, Song HS, Park SH, Sohn CH, Shin SW, Choi JH, Ki CS, Park CK, Holmes AJ, Janne PA, Park K.
View PubMed
-
APMIS. 2006 Sep;114(9):619-25.
Phospho-Stat3 expression and correlation with VEGF, p53, and Bcl-2 in gastric carcinoma using tissue microarray
Choi JH11, Ahn MJ, Park CK, Han HX, Kwon SJ, Lee YY, Kim IS.
View PubMed